<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NEVIRAPINE - nevirapine hemihydrate suspension </strong><br>Aurobindo Pharma Limited<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use nevirapine safely and effectively. See full prescribing information for nevirapine oral suspension, USP.<br><br>NEVIRAPINE oral suspension USP, for oral use<br>Initial U.S. Approval: 1996</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: LIFE-THREATENING (INCLUDING FATAL) HEPATOTOXICITY and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">SKIN REACTIONS</span></span></h1>
<br><h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<br><ul class="Disc">
<li><span class="Bold">Fatal and non-fatal hepatotoxicity <a href="#Section_5.1">(5.1)</a></span></li>
<li>
<span class="Bold">Fatal and non-fatal skin reactions <a href="#Section_5.2">(5.2)</a></span><span class="Bold"></span>
</li>
</ul>
<p class="Highlighta"><span class="Bold">Discontinue immediately if experiencing:</span> </p>
<br><ul class="Disc">
<li>
<span class="Bold">Signs or symptoms of hepatitis <a href="#Section_5.1">(5.1)</a></span><span class="Bold"></span>
</li>
<li>
<span class="Bold">Increased transaminases combined with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other systemic </span><span class="Bold">symptoms <a href="#Section_5.1">(5.1)</a></span>
</li>
<li><span class="Bold">Severe skin or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> <a href="#Section_5.2">(5.2)</a></span></li>
<li><span class="Bold">Any <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with systemic symptoms <a href="#Section_5.2">(5.2)</a></span></li>
</ul>
<p class="Highlighta"><span class="Bold">Monitoring during the first 18 weeks of therapy is essential. Extra vigilance is warranted during the first 6 weeks of therapy, which is the period of greatest risk of these events. <a href="#Section_5">(5)</a></span> </p>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: LIFE-THREATENING (INCLUDING FATAL) HEPATOTOXICITY and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">SKIN REACTIONS</span></span></h1>
<br><h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<br><ul class="Disc">
<li><span class="Bold">Fatal and non-fatal hepatotoxicity <a href="#Section_5.1">(5.1)</a></span></li>
<li>
<span class="Bold">Fatal and non-fatal skin reactions <a href="#Section_5.2">(5.2)</a></span><span class="Bold"></span>
</li>
</ul>
<p class="Highlighta"><span class="Bold">Discontinue immediately if experiencing:</span> </p>
<br><ul class="Disc">
<li>
<span class="Bold">Signs or symptoms of hepatitis <a href="#Section_5.1">(5.1)</a></span><span class="Bold"></span>
</li>
<li>
<span class="Bold">Increased transaminases combined with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other systemic </span><span class="Bold">symptoms <a href="#Section_5.1">(5.1)</a></span>
</li>
<li><span class="Bold">Severe skin or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> <a href="#Section_5.2">(5.2)</a></span></li>
<li><span class="Bold">Any <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with systemic symptoms <a href="#Section_5.2">(5.2)</a></span></li>
</ul>
<p class="Highlighta"><span class="Bold">Monitoring during the first 18 weeks of therapy is essential. Extra vigilance is warranted during the first 6 weeks of therapy, which is the period of greatest risk of these events. <a href="#Section_5">(5)</a></span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<ul class="Disc"><li>Nevirapine is an NNRTI indicated for combination antiretroviral treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in adults and in pediatric patients 15 days and older. <a href="#Section_1">(1)</a>
</li></ul>
<br><p class="Highlighta">Important Considerations: </p>
<ul class="Disc">
<li>Initiation of treatment is not recommended in the following populations unless the benefits outweigh the risks. <a href="#Section_1">(1</a>, <a href="#Section_5.1">5.1)</a><ul class="Disc">
<li>adult females with CD4<span class="Sup">+</span> cell counts greater than 250 cells/mm<span class="Sup">3</span>
</li>
<li>adult males with CD4<span class="Sup">+</span> cell counts greater than 400 cells/mm<span class="Sup">3</span>
</li>
</ul>
</li>
<li>The 14-day lead-in period must be strictly followed; it has been demonstrated to reduce the frequency of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. <a href="#Section_2.4">(2.4</a>, <a href="#Section_5.2">5.2)</a>
</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul class="Disc">
<li>If any patient experiences <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> during the 14-day lead-in period, do not increase dose until the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> has resolved. Do not continue the lead-in dosing regimen beyond 28 days. <a href="#Section_2.4">(2.4)</a>
</li>
<li>If dosing is interrupted for greater than 7 days, restart 14-day lead-in dosing. <a href="#Section_2.4">(2.4)</a>  </li>
</ul>
<table border="0" cellpadding="0" cellspacing="0">
<tfoot><tr class="First Last"><td colspan="3">*Total daily dose should not exceed 400 mg for any patient.<br>
</td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top"> <br>
</td>
<td class="Rrule" valign="top">
<span class="Bold"> Adults</span><br> (≥16 yrs)<br>
</td>
<td class="Rrule" valign="top">
<span class="Bold"> Pediatric Patients*</span><br> (≥15 days)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold"> First 14 days</span><br>
</td>
<td class="Rrule" valign="top"> 200 mg once daily<br>
</td>
<td class="Rrule" valign="top"> 150 mg/m<span class="Sup">2</span> once daily<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">
<span class="Bold"> After 14 days</span><br>
</td>
<td class="Rrule" valign="top"> 200 mg twice daily<br>
</td>
<td class="Rrule" valign="top"> 150 mg/m<span class="Sup">2</span> twice daily<br>
</td>
</tr>
</tbody>
</table>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>50 mg per 5 mL oral suspension <a href="#Section_3">(3)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Patients with moderate or severe (Child-Pugh Class B or C, respectively) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. <a href="#Section_4.1">(4.1</a>, <a href="#Section_5.1">5.1</a>, <a href="#Section_8.7">8.7)</a>
</li>
<li>Use as part of occupational and non-occupational post-exposure prophylaxis (PEP) regimens, an unapproved use. <a href="#Section_4.2">(4.2</a>, <a href="#Section_5.1">5.1)</a>
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Hepatotoxicity: Fatal and non-fatal hepatotoxicity has been reported. Monitor liver function tests before and during therapy. Permanently discontinue nevirapine if clinical <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> or transaminase elevations combined with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other systemic symptoms occur. Do not restart nevirapine after recovery. <a href="#Section_5.1">(5.1)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>: Fatal and non-fatal <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, have been reported. Permanently discontinue nevirapine if severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> occur. Check transaminase levels immediately for all patients who develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in the first 18 weeks of treatment. <a href="#Section_5.2">(5.2)</a>
</li>
<li>Monitor patients for <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">immune reconstitution syndrome</span> and fat redistribution. <a href="#Section_5.5">(5.5</a>, <a href="#Section_5.6">5.6)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc">
<li>The most common adverse reaction is <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. In adults the incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is 15% versus 6% with placebo, with Grade 3/4 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> occurring in 2% of subjects. <a href="#Section_6.1">(6.1)</a>
</li>
<li>In pediatric subjects the incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (all causality) was 21%. <a href="#Section_6.2">(6.2)</a>
</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. </span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<br><p class="Highlighta">Co-administration of nevirapine  </p>
<span class="Bold"></span><p class="Highlighta">can alter the concentrations of other drugs and other drugs may alter the concentration of nevirapine. The potential for drug interactions must be considered prior to and during therapy. <a href="#Section_5.4">(5.4</a>, <a href="#Section_7">7</a>, <a href="#Section_12.3">12.3)</a> </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>No dose adjustment is required for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> with a creatinine clearance greater than or equal to 20 mL per min. Patients on dialysis receive an additional dose of 200 mg following each dialysis treatment. (<a href="#Section_2.4">2.4</a>, <a href="#Section_8.6">8.6</a>)</li>
<li>Monitor patients with <span class="product-label-link" type="condition" conceptid="4267417" conceptname="Hepatic fibrosis">hepatic fibrosis</span> or cirrhosis carefully for evidence of drug induced toxicity. Do not administer nevirapine to patients with Child-Pugh B or C. (<a href="#Section_5.1">5.1</a>, <a href="#Section_8.7">8.7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 4/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: LIFE-THREATENING (INCLUDING FATAL) HEPATOTOXICITY and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">SKIN REACTIONS</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adult Patients</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Pediatric Patients</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Monitoring of Patients</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dosage Adjustment</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Post-Exposure Prophylaxis</a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Hepatotoxicity and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Resistance</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Drug Interactions</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Fat Redistribution</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience in Adult Patients</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Clinical Trial Experience in Pediatric Patients</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Adult Patients</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Pediatric Patients</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="Section_0"></a><a name="section-1"></a><p></p>
<h1>WARNING: LIFE-THREATENING (INCLUDING FATAL) HEPATOTOXICITY and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">SKIN REACTIONS</span></h1>
<br><p class="First"><span class="Bold">HEPATOTOXICITY:</span><br><br><span class="Bold">Severe, life-threatening, and in some cases fatal hepatotoxicity, particularly in the first 18 weeks, has been reported in patients treated with nevirapine. In some cases, patients presented with non-specific prodromal signs or symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and progressed to <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>. These events are often associated with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Female gender and higher CD4<span class="Sup">+</span> cell counts at initiation of therapy place patients at increased risk; women with CD4<span class="Sup">+</span> cell counts greater than 250 cells/mm<span class="Sup">3</span>, including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, are at the greatest risk. However, hepatotoxicity associated with nevirapine use can occur in both genders, all CD4<span class="Sup">+</span> cell counts and at any time during treatment. Hepatic failure has also been reported in patients without HIV taking nevirapine for post-exposure prophylaxis (PEP). Use of nevirapine for occupational and non-occupational PEP is contraindicated <span class="Italics">[see <a href="#Section_4.2">Contraindications (4.2)</a>]</span></span><span class="Bold">. Patients with signs or symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, or with increased transaminases combined with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other systemic symptoms, must discontinue nevirapine and seek medical evaluation immediately <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span></span>.<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">SKIN REACTIONS</span>:</span><br><br><span class="Bold">Severe, life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, including fatal cases, have occurred in patients treated with nevirapine. These have included cases of <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> characterized by <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, constitutional findings, and organ dysfunction. Patients developing signs or symptoms of severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> must discontinue nevirapine and seek medical evaluation immediately. Transaminase levels should be checked immediately for all patients who develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in the first 18 weeks of treatment. The 14-day lead-in period with nevirapine 200 mg daily dosing has been observed to decrease the incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and must be followed <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>]</span></span>.<br><br><span class="Bold">MONITORING:<br> <br></span><span class="Bold"><span class="Bold">Patients must be monitored intensively during the first 18 weeks of therapy with nevirapine to detect potentially life-threatening hepatotoxicity or <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. Extra vigilance is warranted during the first 6 weeks of therapy, which is the period of greatest risk of these events. Do not restart nevirapine following clinical <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, or transaminase elevations combined with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other systemic symptoms, or following severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. In some cases, hepatic injury has progressed despite discontinuation of treatment.</span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<br><p class="First">Nevirapine oral suspension, USP is indicated for combination antiretroviral treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in adults and in pediatric patients 15 days and older <span class="Italics">[see <a href="#Section_14.1">Clinical Studies (14.1</a>, <a href="#Section_14.2">14.2)</a>]</span>. <br><br>Additional important information regarding the use of nevirapine oral suspension, USP for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>:</p>
<br><ul class="Disc">
<li>Based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled trials, nevirapine oral suspension, USP should not be initiated in adult females with CD4<span class="Sup">+</span> cell counts greater than 250 cells/mm<span class="Sup">3</span> or in adult males with CD4<span class="Sup">+</span> cell counts greater than 400 cells/mm<span class="Sup">3</span> unless the benefit outweighs the risk <span class="Italics">[see <a href="#Section_0">Boxed Warning</a> and <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span>.<span class="Italics"></span>
</li>
<li>The 14-day lead-in period with nevirapine oral suspension USP,200 mg daily dosing must be strictly followed; it has been demonstrated to reduce the frequency of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> <span class="Italics">[see <span class="Italics"><a href="#Section_2.4">Dosage and Administration  (2.4)</a></span></span><span class="Italics">and <span class="Italics"><a href="#Section_5.2">Warnings and Precautions (5.2)</a></span>]</span>.<span class="Italics"></span>
</li>
<li>If <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> persists beyond the 14-day lead-in period, do not dose escalate to 200 mg twice daily. The 200 mg once-daily dosing regimen should not be continued beyond 28 days, at which point an alternative regimen should be sought.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adult Patients</h2>
<br><p class="First">The recommended dose for nevirapine oral suspension is 200 mg daily for the first 14 days, followed by 200 mg twice daily, in combination with other antiretroviral agents. The lead-in period has been observed to decrease the incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. For concomitantly administered antiretroviral therapy, the manufacturer’s recommended dosage and monitoring should be followed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Pediatric Patients</h2>
<br><p class="First">The recommended oral dose for pediatric patients 15 days and older is 150 mg/m<span class="Sup">2</span> once daily for 14 days followed by 150 mg/m<span class="Sup">2</span> twice daily thereafter. The total daily dose should not exceed 400 mg for any patient.</p>
<br><div class="Figure"><img alt="Mosteller Formula " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8dfe86aa-ea5d-48d2-94a8-1a5506055d70&amp;name=nevirapine-fig1.jpg"></div>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 1 Calculation of the Volume of Nevirapine Oral Suspension (50 mg per 5 mL) Required for Pediatric Dosing Based on Body Surface and a Dose of 150 mg/m<span class="Sup">2</span></span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule" align="center">BSA range (m<span class="Sup">2</span>)</th>
<th class="Lrule Rrule Toprule" align="center">Volume (mL)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">0.06 – 0.12<br>
</td>
<td class="Rrule" align="center" valign="top">1.25<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">0.12 – 0.25<br>
</td>
<td class="Rrule" align="center" valign="top">2.5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">0.25 – 0.42<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">0.42 – 0.58<br>
</td>
<td class="Rrule" align="center" valign="top">7.5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">0.58 – 0.75<br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">0.75 – 0.92<br>
</td>
<td class="Rrule" align="center" valign="top">12.5<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">0.92 – 1.08<br>
</td>
<td class="Rrule" align="center" valign="top">15<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">1.08 – 1.25<br>
</td>
<td class="Rrule" align="center" valign="top">17.5<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">1.25+<br>
</td>
<td class="Rrule" align="center" valign="top">20<br>
</td>
</tr>
</tbody>
</table>
<p>Nevirapine suspension should be shaken gently prior to administration. It is important to administer the entire measured dose of suspension by using an oral dosing syringe or dosing cup. An oral dosing syringe is recommended, particularly for volumes of 5 mL or less. If a dosing cup is used, it should be thoroughly rinsed with water and the rinse should also be administered to the patient.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Monitoring of Patients</h2>
<br><p class="First">Intensive clinical and laboratory monitoring, including liver enzyme tests, is essential at baseline and during the first 18 weeks of treatment with nevirapine oral suspension. The optimal frequency of monitoring during this period has not been established. Some experts recommend clinical and laboratory monitoring more often than once per month, and in particular, would include monitoring of liver enzyme tests at baseline, prior to dose escalation, and at two weeks post-dose escalation. After the initial 18-week period, frequent clinical and laboratory monitoring should continue throughout nevirapine oral suspension treatment <span class="Italics">[see <a href="#Section_5">Warnings and Precautions (5)</a>]</span>. In some cases, hepatic injury has progressed despite discontinuation of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dosage Adjustment</h2>
<br><p class="First"><span class="Italics"><span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></span></span><br><br><span class="Bold">Discontinue n</span><span class="Bold">evirapine oral suspension </span><span class="Bold">if a patient experiences severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or any <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> accompanied by constitutional findings <span class="Italics"></span></span><span class="Italics">[see <a href="#Section_0">Boxed Warning</a> and <a href="#Section_5.2">Warnings and Precautions (5.2)</a>]</span>. </p>
<span class="Bold"></span><p><span class="Bold">Do not increase </span><span class="Bold">nevirapine oral suspension dose if a patient experiences </span><span class="Bold">mild to moderate <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> without constitutional symptoms during the 14-day lead-in period of 200 mg/day (150 mg/m<span class="Sup">2</span>/day in pediatric patients) until the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> has resolved </span><span class="Italics">[see <span class="Italics"><a href="#Section_5.2">Warnings  and Precautions (5.2)</a></span></span><span class="Italics">]</span>.<span class="Bold"> The total duration of the once daily lead-in dosing period should not exceed 28 days at which point an alternative regimen should be sought.</span><br><br><span class="Italics"><span class="Bold">Patients with Hepatic Events</span></span><br><br><span class="Bold">If a clinical (symptomatic) hepatic event occurs, permanently discontinue nevirapine oral suspension. Do not restart nevirapine oral suspension after recovery </span><span class="Italics">[see <span class="Italics"><a href="#Section_5.1">Warnings and Precautions (5.1)</a></span>]</span>.<br><br><span class="Italics"><span class="Bold">Patients with Dose Interruption</span></span><br><br>For patients who interrupt nevirapine oral suspension dosing for more than 7 days, restart the recommended dosing, 200 mg daily (150 mg/m<span class="Sup">2</span>/day in pediatric patients) for the first 14 days (lead-in) followed by 200 mg twice daily (150 mg/m<span class="Sup">2</span> twice daily for pediatric patients).<br><br><span class="Italics"><span class="Bold">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span><br> <br></span>Patients with CrCL greater than or equal to 20 mL per min do not require an adjustment in nevirapine oral suspension dosing. The pharmacokinetics of nevirapine have not been evaluated in patients with CrCL less than 20 mL per min. An additional 200 mg dose of nevirapine oral suspension following each dialysis treatment is indicated in patients requiring dialysis. Nevirapine metabolites may accumulate in patients receiving dialysis; however, the clinical significance of this accumulation is not known<span class="Italics"> [see <span class="Italics"><a href="#Section_12.3">Clinical Pharmacology (12.3)</a></span>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<br><p class="First">Nevirapine oral suspension is a white to off-white homogenous suspension containing 50 mg nevirapine (as nevirapine hemihydrate) in each 5 mL.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<br><p class="First">Nevirapine oral suspension is contraindicated in patients with moderate or severe (Child-Pugh Class B or C, respectively) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a></span><span class="Italics"> and <a href="#Section_8.7">Use in Specific Populations (8.7)</a></span><span class="Italics">]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Post-Exposure Prophylaxis</h2>
<br><p class="First">Nevirapine oral suspension is contraindicated for use as part of occupational and non-occupational post-exposure prophylaxis (PEP) regimens <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<br><p class="First">The most serious adverse reactions associated with nevirapine are <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>/<span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>/<span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> may be associated with signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> which can include severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> accompanied by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="43530620" conceptname="Oral lesion">oral lesions</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, or renal dysfunction.<br><br><span class="Bold">The first 18 weeks of therapy with nevirapine are a critical period during which intensive clinical and laboratory monitoring of patients is required to detect potentially life-threatening hepatic events and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>.</span> The optimal frequency of monitoring during this time period has not been established. Some experts recommend clinical and laboratory monitoring more often than once per month, and in particular, include monitoring of liver enzyme tests at baseline, prior to dose escalation and at two weeks post-dose escalation. After the initial 18-week period, frequent clinical and laboratory monitoring should continue throughout nevirapine treatment. In addition, the 14-day lead-in period with nevirapine 200 mg daily dosing has been demonstrated to reduce the frequency of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> <span class="Italics">[see <a href="#Section_2.1">Dosage and Administration (2.1)</a>]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Hepatotoxicity and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<br><p class="First">Severe, life-threatening, and in some cases fatal hepatotoxicity, including fulminant and <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, have been reported in patients treated with nevirapine. In controlled clinical trials, symptomatic hepatic events regardless of severity occurred in 4% (range 0% to 11%) of subjects who received nevirapine and 1% of subjects in control groups.<br><br>The risk of symptomatic hepatic events regardless of severity was greatest in the first 6 weeks of therapy. The risk continued to be greater in the nevirapine groups compared to controls through 18 weeks of treatment. However, hepatic events may occur at any time during treatment. In some cases, subjects presented with non­-specific, prodromal signs or symptoms of <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4010482" conceptname="Liver tender">liver tenderness</span> or <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, with or without initially abnormal serum transaminase levels. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> was observed in approximately half of the subjects with symptomatic hepatic adverse events. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> and flu-like symptoms accompanied some of these hepatic events. Some events, particularly those with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and other symptoms, have progressed to <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> with transaminase elevation, with or without <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>, <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>, prolonged partial thromboplastin time, or <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>. <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> has been observed in some patients experiencing skin and/or liver reactions associated with nevirapine use. Patients with signs or symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> must be advised to discontinue nevirapine and immediately seek medical evaluation, which should include liver enzyme tests.<br><br><span class="Bold">Transaminases should be checked immediately if a patient experiences signs or symptoms suggestive of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and/or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. Transaminases should also be checked immediately for all patients who develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in the first 18 weeks of treatment. Physicians and patients should be vigilant for the appearance of signs or symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, such as <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4172937" conceptname="Bilirubinuria">bilirubinuria</span>, acholic stools, <span class="product-label-link" type="condition" conceptid="4010482" conceptname="Liver tender">liver tenderness</span> or <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>. The diagnosis of hepatotoxicity should be considered in this setting, even if transaminases are initially normal or alternative diagnoses are possible </span><span class="Italics"><span class="Bold">[see <a href="#Section_0">Boxed Warning and</a> <a href="#Section_2.3">Dosage and Administration (2.3)</a>]</span></span>.<br><br>If clinical <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> or transaminase elevations combined with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other systemic symptoms occur, permanently discontinue nevirapine . Do not restart nevirapine after recovery. In some cases, hepatic injury progresses despite discontinuation of treatment. <br><br>The patients at greatest risk of hepatic events, including potentially fatal events, are women with high CD4<span class="Sup">+</span> cell counts. In general, during the first 6 weeks of treatment, women have a 3-fold higher risk than men for symptomatic, often <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>-associated, hepatic events (6% versus 2%), and patients with higher CD4<span class="Sup">+</span> cell counts at initiation of nevirapine therapy are at higher risk for symptomatic hepatic events with nevirapine. In a retrospective review, women with CD4<span class="Sup">+</span> cell counts greater than 250 cells/mm<span class="Sup">3</span> had a 12-fold higher risk of symptomatic hepatic adverse events compared to women with CD4<span class="Sup">+</span> cell counts less than 250 cells/mm<span class="Sup">3</span> (11% versus 1%). An increased risk was observed in men with CD4<span class="Sup">+</span> cell counts greater than 400 cells/mm<span class="Sup">3</span> (6% versus 1% for men with CD4<span class="Sup">+</span> cell counts less than 400 cells/mm<span class="Sup">3</span>). However, all patients, regardless of gender, CD4<span class="Sup">+</span> cell count, or antiretroviral treatment history, should be monitored for hepatotoxicity since symptomatic hepatic adverse events have been reported at all CD4<span class="Sup">+</span></p>
<span class="Bold"></span><p>cell </p>
<span class="Bold"></span><p>counts. Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C and/or increased transaminase elevations at the start of therapy with nevirapine are associated with a greater risk of later symptomatic events (6 weeks or more after starting nevirapine) and asymptomatic increases in AST or ALT. <br><br>In addition, serious hepatotoxicity (including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> requiring transplantation in one instance) has been reported in HIV-1 uninfected individuals receiving multiple doses of nevirapine in the setting of post-exposure prophylaxis (PEP), an unapproved use. Use of nevirapine for occupational and non-occupational PEP is contraindicated <span class="Italics">[see <a href="#Section_4.2">Contraindications (4.2)</a>].</span> <br><br>Increased nevirapine trough concentrations have been observed in some patients with <span class="product-label-link" type="condition" conceptid="4267417" conceptname="Hepatic fibrosis">hepatic fibrosis</span> or cirrhosis. Therefore, carefully monitor patients with either <span class="product-label-link" type="condition" conceptid="4267417" conceptname="Hepatic fibrosis">hepatic fibrosis</span> or cirrhosis for evidence of drug-induced toxicity. Do not administer nevirapine to patients with moderate or severe (Child-Pugh Class B or C, respectively) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#Section_4.1">Contraindications (4.1)</a>, <a href="#Section_8.7">Use in Specific Populations (8.7)</a>, and <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<br><p class="First">Severe and life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, including fatal cases, have been reported, occurring most frequently during the first 6 weeks of therapy. These have included cases of <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> characterized by <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, constitutional findings, and organ dysfunction including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>. <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span> has been observed in some patients experiencing skin and/or liver reactions associated with nevirapine use. In controlled clinical trials, Grade 3 and 4 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> were reported during the first 6 weeks in 2% of nevirapine recipients compared to less than 1% of placebo subjects.<br><br>Patients developing signs or symptoms of severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (including, but not limited to, severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> accompanied by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="43530620" conceptname="Oral lesion">oral lesions</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and/or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, and renal dysfunction) must permanently discontinue nevirapine and seek medical evaluation immediately <span class="Italics">[see <a href="#Section_0">Boxed Warning</a></span><span class="Italics">]</span>. Do not restart nevirapine following severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> combined with increased transaminases or other symptoms, or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>.<br><br>If patients present with a suspected nevirapine-associated <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, measure transaminases immediately. Permanently discontinue nevirapine in patients with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>-associated transaminase elevations <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span>.<br><br>Therapy with nevirapine must be initiated with a 14-day lead-in period of 200 mg per day (150 mg/m<span class="Sup">2</span> per day in pediatric patients), which has been shown to reduce the frequency of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Discontinue nevirapine if a patient experiences severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or any <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> accompanied by constitutional findings. Do not increase nevirapine dose to a patient experiencing a mild to moderate <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> without constitutional symptoms during the 14-day lead-in period of 200 mg per day (150 mg/m<span class="Sup">2</span>/day in pediatric patients) until the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> has resolved<span class="Italics">. </span>The total duration of the once-daily lead-in dosing period must not exceed 28 days at which point an alternative regimen should be sought <span class="Italics">[see <a href="#Section_2.4">Dosage and Administration (2.4)</a>]</span>. Patients must be monitored closely if isolated <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> of any severity occurs. Delay in stopping nevirapine treatment after the onset of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> may result in a more serious reaction. <br><br>Women appear to be at higher risk than men of developing <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with nevirapine.<br><br>In a clinical trial, concomitant prednisone use (40 mg per day for the first 14 days of nevirapine administration) was associated with an increase in incidence and severity of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> during the first 6 weeks of nevirapine therapy. Therefore, use of prednisone to prevent nevirapine-associated <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Resistance</h2>
<br><p class="First">Nevirapine must not be used as a single agent to treat HIV-1 or added on as a sole agent to a failing regimen. Resistant virus emerges rapidly when nevirapine is administered as monotherapy. The choice of new antiretroviral agents to be used in combination with nevirapine should take into consideration the potential for cross resistance. When discontinuing an antiretroviral regimen containing nevirapine, the long half-life of nevirapine should be taken into account; if antiretrovirals with shorter half-lives than nevirapine are stopped concurrently, low plasma concentrations of nevirapine alone may persist for a week or longer and virus resistance may subsequently develop <span class="Italics">[see <a href="#Section_12.4">Microbiology (12.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Drug Interactions</h2>
<br><p class="First">See Table 4 for listings of established and potential drug interactions <span class="Italics">[see <a href="#Section_7">Drug Interactions (7)</a>]</span>.<br><br>Concomitant use of St. John's wort (<span class="Italics">Hypericum perforatum</span>) or St. John's wort-containing products and nevirapine is not recommended. Co-administration of St. John’s wort with non-nucleoside reverse transcriptase inhibitors (NNRTIs), including nevirapine, is expected to substantially decrease NNRTI concentrations and may result in sub-optimal levels of nevirapine and lead to loss of virologic response and possible resistance to nevirapine or to the class of NNRTIs. Co-administration of nevirapine and efavirenz is not recommended as this combination has been associated with an increase in adverse reactions and no improvement in efficacy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></h2>
<br><p class="First"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including nevirapine. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (such as <span class="Italics">Mycobacterium avium </span><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis jiroveci </span><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>), which may necessitate further evaluation and treatment.<br><br><span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune disorders</span> (such as Graves’ disease, <span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>, and Guillain-Barré syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Fat Redistribution</h2>
<br><p class="First">Redistribution/accumulation of body fat including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and “cushingoid appearance? have been observed in patients receiving antiretroviral therapy. The mechanism and long-term consequences of these events are currently unknown. A causal relationship has not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience in Adult Patients</h2>
<br><p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.<br><br>The most serious adverse reactions associated with nevirapine are <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>/<span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> may be isolated or associated with signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> which may include severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> accompanied by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="43530620" conceptname="Oral lesion">oral lesions</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, or renal dysfunction <span class="Italics">[see <a href="#Section_0">Boxed Warning</a> and <a href="#Section_5.1">Warnings and Precautions (5.1</a>, <a href="#Section_5.2">5.2)</a>].</span><br><br><span class="Italics"><span class="Bold">Hepatic Reaction</span></span><br><br>In controlled clinical trials, symptomatic hepatic events regardless of severity occurred in 4% (range 0% to 11%) of subjects who received nevirapine and 1% of subjects in control groups. Female gender and higher CD4<span class="Sup">+</span> cell counts (greater than 250 cells/mm<span class="Sup">3</span> in women and greater than 400 cells/mm<span class="Sup">3</span> in men) place patients at increased risk of these events <span class="Italics">[see <a href="#Section_0">Boxed Warning</a> and <a href="#Section_5.1">Warnings and Precautions (5.1)</a>].</span><br><br>Asymptomatic transaminase elevations (AST or ALT greater than 5X ULN) were observed in 6% (range 0% to 9%) of subjects who received nevirapine and 6% of subjects in control groups. Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C and/or increased transaminase elevations at the start of therapy with nevirapine are associated with a greater risk of later symptomatic events (6 weeks or more after starting nevirapine) and asymptomatic increases in AST or ALT. <br><br>Liver enzyme abnormalities (AST, ALT, GGT) were observed more frequently in subjects receiving nevirapine than in controls (see Table 3).<br><span class="Italics"><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reaction</span></span></span><br><br>The most common clinical toxicity of nevirapine is <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, which can be severe or life-threatening <span class="Italics">[see <a href="#Section_0">Boxed Warning</a> and <a href="#Section_5.2">Warnings and Precautions (5.2)</a>]</span>. </p>
<span class="Italics"></span><p><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> occurs most frequently within the first 6 weeks of therapy. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rashes</span> are usually mild to moderate, maculopapular erythematous cutaneous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruptions</span>, with or without <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, located on the trunk, face and extremities. In controlled clinical trials (Trials 1037, 1038, 1046, and 1090), Grade 1 and 2 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> were reported in 13% of subjects receiving nevirapine compared to 6% receiving placebo during the first 6 weeks of therapy. Grade 3 and 4 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> were reported in 2% of nevirapine recipients compared to less than 1% of subjects receiving placebo. Women tend to be at higher risk for development of nevirapine-associated <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> <span class="Italics">[see <a href="#Section_0">Boxed Warning</a> and <a href="#Section_5.2">Warnings and Precautions (5.2)</a></span><span class="Italics">]</span>.<br><br>Treatment-related, adverse experiences of moderate or severe intensity observed in greater than 2% of subjects receiving nevirapine in placebo-controlled trials are shown in Table 2.  </p>
<br><table border="0" cellpadding="0" cellspacing="0" width="610">
<caption><span>Table 2 Percentage of Subjects with Moderate or Severe Drug-Related Events in Adult Placebo-Controlled Trials 
			</span></caption>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" rowspan="2"></th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">Trial 1090<span class="Sup">1</span>
</th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">Trials 1037, 1038, 1046<span class="Sup">2</span>
</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center">Nevirapine<br>(n=1121)</th>
<th class="Lrule Rrule Toprule" align="center">Placebo<br>(n=1128)</th>
<th class="Lrule Rrule Toprule" align="center">Nevirapine<br>(n=253)</th>
<th class="Lrule Rrule Toprule" align="center">Placebo<br>(n=203)</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="5">
<span class="Sup">1 </span>Background therapy included 3TC for all subjects and combinations of NRTIs and PIs. Subjects had CD4<span class="Sup">+</span> cell counts less than 200 cells/mm<span class="Sup">3</span>.<br><span class="Sup">2 </span>Background therapy included ZDV and ZDV+ddI; nevirapine monotherapy was administered in some subjects. Subjects had CD4<span class="Sup">+</span> cell count greater than or equal to 200 cells/mm<span class="Sup">3</span>.<br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top"> Median exposure (weeks)<br>
</td>
<td class="Rrule" align="center" valign="top">58<br>
</td>
<td class="Rrule" align="center" valign="top">52<br>
</td>
<td class="Rrule" align="center" valign="top">28<br>
</td>
<td class="Rrule" align="center" valign="top">28<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> Any adverse event<br>
</td>
<td class="Rrule" align="center" valign="top">15%<br>
</td>
<td class="Rrule" align="center" valign="top">11%<br>
</td>
<td class="Rrule" align="center" valign="top">32%<br>
</td>
<td class="Rrule" align="center" valign="top">13%<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span><br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">Granulocytopenia</span><br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">&lt;1<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span><br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">&lt;1<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span><br>
</td>
<td class="Rrule" align="center" valign="top">&lt;1<br>
</td>
<td class="Rrule" align="center" valign="top">&lt;1<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span><br>
</td>
<td class="Rrule" align="center" valign="top">&lt;1<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span><br>
</td>
<td class="Rrule" align="center" valign="top">&lt;1<br>
</td>
<td class="Rrule" align="center" valign="top">&lt;1<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top"> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span><br>
</td>
<td class="Rrule" align="center" valign="top">&lt;1<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
</tbody>
</table>
<br><p><span class="Italics">Laboratory Abnormalities</span><br><br>Liver enzyme test abnormalities (AST, ALT) were observed more frequently in subjects receiving nevirapine than in controls (Table 3). Asymptomatic elevations in GGT occur frequently but are not a contraindication to continue nevirapine therapy in the absence of elevations in other liver enzyme tests. Other laboratory abnormalities (bilirubin, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>) were observed with similar frequencies in clinical trials comparing nevirapine and control regimens (see Table 3).</p>
<br><table border="0" cellpadding="0" cellspacing="0" width="600">
<caption><span>Table 3 Percentage of Adult Subjects with Laboratory Abnormalities 
			</span></caption>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule" rowspan="2">Laboratory Abnormality</th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">Trial 1090<span class="Sup">1</span>
</th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">Trials 1037, 1038, 1046<span class="Sup">2</span>
</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center">Nevirapine<br>(n=1121)</th>
<th class="Lrule Rrule Toprule" align="center">Placebo<br>(n=1128)</th>
<th class="Lrule Rrule Toprule" align="center">Nevirapine<br>(n=253)</th>
<th class="Lrule Rrule Toprule" align="center">Placebo<br>(n=203)</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="5">
<span class="Sup">1 </span>Background therapy included 3TC for all subjects and combinations of NRTIs and PIs. Subjects had CD4<span class="Sup">+</span> cell counts less than 200 cells/mm<span class="Sup">3</span>.<br><span class="Sup">2 </span>Background therapy included ZDV and ZDV+ddI; nevirapine monotherapy was administered in some subjects. Subjects had CD4<span class="Sup">+</span> cell count greater than or equal to 200 cells/mm<span class="Sup">3</span>.<br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" colspan="5" valign="top">
<span class="Bold"> Blood Chemistry</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">     SGPT (ALT) &gt;250 U/L<br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">14<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">     <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> (AST) &gt;250 U/L<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">     Bilirubin &gt;2.5 mg/dL<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="5" valign="top">
<span class="Bold"> Hematology</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">     Hemoglobin &lt;8 g/dL<br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">     Platelets &lt;50,000/mm<span class="Sup">3</span><br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">&lt;1<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">     <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> &lt;750/mm<span class="Sup">3</span><br>
</td>
<td class="Rrule" align="center" valign="top">13<br>
</td>
<td class="Rrule" align="center" valign="top">14<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Clinical Trial Experience in Pediatric Patients</h2>
<br><p class="First">Adverse events were assessed in BI Trial 1100.1032 (ACTG 245), a double-blind, placebo-controlled trial of nevirapine (n=305) in which pediatric subjects received combination treatment with nevirapine. In this trial two subjects were reported to experience <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> or Stevens-Johnson/<span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> transition syndrome. Safety was also assessed in trial BI 1100.882 (ACTG 180), an open-label trial of nevirapine (n=37) in which subjects were followed for a mean duration of 33.9 months (range: 6.8 months to 5.3 years, including long-term follow-up in 29 of these subjects in trial BI 1100.892). The most frequently reported adverse events related to nevirapine in pediatric subjects were similar to those observed in adults, with the exception of <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, which was more commonly observed in children receiving both zidovudine and nevirapine. Cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, including one case of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, were also reported.<br><br>The safety of nevirapine was also examined in BI Trial 1100.1368, an open-label, randomized clinical trial performed in South Africa in which 123 HIV-1 infected treatment-naïve subjects between 3 months and 16 years of age received combination treatment with nevirapine oral suspension, lamivudine and zidovudine for 48 weeks <span class="Italics">[see <a href="#Section_8.4">Use in Specific Populations (8.4)</a> and <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>. </p>
<span class="Italics"></span><p><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (all causality) was reported in 21% of the subjects, 4 (3%) of whom discontinued drug due to <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. All 4 subjects experienced the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> early in the course of therapy (less than 4 weeks) and resolved upon nevirapine discontinuation. Other clinically important adverse events (all causality) include <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (9%), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (7%), and hepatotoxicity (2%) <span class="Italics">[see <a href="#Section_8.4">Use in Specific Populations (8.4)</a> and <a href="#Section_14.2">Clinical Studies (14.2)</a>]</span>.<br><br>Safety information on use of nevirapine in combination therapy in pediatric subjects 2 weeks to less than 3 months of age was assessed in 36 subjects from the BI 1100.1222 (PACTG 356) trial. No unexpected safety findings were observed although <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> was reported more frequently in this age group compared to the older pediatric age groups and adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Post-Marketing Experience</h2>
<br><p class="First">In addition to the adverse events identified during clinical trials, the following adverse reactions have been identified during post-approval use of nevirapine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.<br><br><span class="Italics">Body as a Whole: </span><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, drug withdrawal <span class="Italics">[see <a href="#Section_7">Drug Interactions (7)</a>], </span>redistribution/accumulation of body fat <span class="Italics">[see <a href="#Section_5.6">Warnings and Precautions (5.6)</a>]</span><br><br><span class="Italics">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span><br><br><span class="Italics">Liver and Biliary: </span><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, fulminant and <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">cholestatic hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span><br><br><span class="Italics">Hematology: </span><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span><br><br><span class="Italics">Investigations: </span>decreased serum phosphorus<br><br><span class="Italics">Musculoskeletal: </span><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> associated with skin and/or liver reactions<br><br><span class="Italics">Neurologic: </span><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span><br><br><span class="Italics">Skin and Appendages: </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">bullous eruptions</span>, <span class="product-label-link" type="condition" conceptid="4160872" conceptname="Recurrent aphthous ulcer">ulcerative stomatitis</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> have all been reported. In addition, <span class="product-label-link" type="condition" conceptid="45765791" conceptname="Drug reaction with eosinophilia and systemic symptoms">hypersensitivity syndrome</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> associated with constitutional findings such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, <span class="product-label-link" type="condition" conceptid="43530620" conceptname="Oral lesion">oral lesions</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, or significant hepatic abnormalities, drug reaction with <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and systemic symptoms (DRESS) <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a>] </span>plus one or more of the following: <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, and/or renal dysfunction have been reported. <br><br>In post-marketing surveillance <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> has been more commonly observed in children although development of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> due to concomitant medication use cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Nevirapine is principally metabolized by the liver via the cytochrome P450 isoenzymes, 3A and 2B6. Nevirapine is known to be an inducer of these enzymes. As a result, drugs that are metabolized by these enzyme systems may have lower than expected plasma levels when co-administered with nevirapine.<br><br>The specific pharmacokinetic changes that occur with co-administration of nevirapine and other drugs are listed in <span class="Italics">Clinical Pharmacology</span>, Table 5. Clinical comments about possible dosage modifications based on established drug interactions are listed in Table 4. The data in Tables 4 and 5 are based on the results of drug interaction trials conducted in HIV-1 seropositive subjects unless otherwise indicated. In addition to established drug interactions, there may be potential <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> between nevirapine and other drug classes that are metabolized by the cytochrome P450 system. These potential drug interactions are also listed in Table 4. Although specific drug interaction trials in HIV-1 seropositive subjects have not been conducted for some classes of drugs listed in Table 4, additional clinical monitoring may be warranted when co-administering these drugs.<br><br>The <span class="Italics">in vitro</span> interaction between nevirapine and the antithrombotic agent warfarin is complex. As a result, when giving these drugs concomitantly, plasma warfarin levels may change with the potential for increases in coagulation time. When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.</p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 4 Established and Potential Drug Interactions: Use With Caution, Alteration in Dose or Regimen May Be Needed Due to Drug Interaction Established Drug Interactions: See Clinical Pharmacology (12.3), Table 5 for Magnitude of Interaction.  
			</span></caption>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">Drug Name</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Effect on Concentration of Nevirapine or Concomitant Drug</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Clinical Comment</span><br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="3" valign="top">
<span class="Bold">HIV Antiviral Agents: Protease Inhibitors (PIs)</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Atazanavir/Ritonavir*<br>
</td>
<td class="Rrule" valign="top">↓ Atazanavir<br>↑ Nevirapine<br>
</td>
<td class="Rrule" valign="top">Do not co-administer nevirapine with atazanavir because nevirapine substantially decreases atazanavir exposure and there is a potential risk for nevirapine-associated toxicity due to increased nevirapine exposures. <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Fosamprenavir*<br>
</td>
<td class="Rrule" valign="top">↓Amprenavir<br>↑Nevirapine<br>
</td>
<td class="Rrule" valign="top">Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Fosamprenavir/Ritonavir*<br>
</td>
<td class="Rrule" valign="top">↓Amprenavir<br>↑Nevirapine <br>
</td>
<td class="Rrule" valign="top">No dosing adjustments are required when nevirapine is co-administered with 700/100 mg of fosamprenavir/ritonavir twice daily. The combination of nevirapine administered with fosamprenavir/ritonavir once daily has not been studied. <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Indinavir* <br>
</td>
<td class="Rrule" valign="top">↓ Indinavir <br>
</td>
<td class="Rrule" valign="top">The appropriate doses of this combination of indinavir and nevirapine with respect to efficacy and safety have not been established. <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Lopinavir/Ritonavir* <br>
</td>
<td class="Rrule" valign="top">↓Lopinavir <br>
</td>
<td class="Rrule" valign="top">Dosing in adult patients: <br> <br>A dose adjustment of lopinavir/ritonavir to 500/125 mg tablets twice daily or 533/133 mg (6.5 mL) oral solution twice daily is recommended when used in combination with nevirapine. Neither lopinavir/ritonavir tablets nor oral solution should be administered once daily in combination with nevirapine.<br> <br>Dosing in pediatric patients: <br> <br>Please refer to the Kaletra<span class="Sup">®</span> prescribing information for dosing recommendations based on body surface area and body weight. Neither lopinavir/ritonavir tablets nor oral solution should be administered once daily in combination with nevirapine.  <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Nelfinavir* <br>
</td>
<td class="Rrule" valign="top">↓ Nelfinavir M8 Metabolite <br>            ↓ Nelfinavir C<span class="Sub">min</span><br>
</td>
<td class="Rrule" valign="top">The appropriate doses of the combination of nevirapine and nelfinavir with respect to safety and efficacy have not been established. <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Saquinavir/ritonavir<br>
</td>
<td class="Rrule" valign="top">The interaction between nevirapine and saquinavir/ritonavir has not been evaluated<br>
</td>
<td class="Rrule" valign="top">The appropriate doses of the combination of nevirapine and saquinavir/ritonavir with respect to safety and efficacy have not been established.<br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="3" valign="top">
<span class="Bold">HIV Antiviral Agents: Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Efavirenz* <br>
</td>
<td class="Rrule" valign="top">↓ Efavirenz  <br>
</td>
<td class="Rrule" valign="top">The appropriate doses of these combinations with respect to safety and efficacy have not been established.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Delavirdine<br>Etravirine<br>Rilpivirine<br>
</td>
<td class="Rrule" valign="top"> <br>
</td>
<td class="Rrule" valign="top">Plasma concentrations may be altered.  Nevirapine should not be coadministered with another NNRTI as this combination has not been shown to be beneficial.<br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="3" valign="top">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C Antiviral Agents</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Boceprevir<br>
</td>
<td class="Rrule" valign="top">Plasma concentrations of boceprevir may be decreased due to induction of CYP3A4/5 by nevirapine.<br>
</td>
<td class="Rrule" valign="top">Nevirapine and boceprevir should not be coadministered because decreases in boceprevir plasma concentrations may result in a reduction in efficacy.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Telaprevir<br>
</td>
<td class="Rrule" valign="top">Plasma concentrations of telaprevir may be decreased due to induction of CYP3A4 by nevirapine and plasma concentrations of nevirapine may be increased due to inhibition of CYP3A4 by telaprevir.<br>
</td>
<td class="Rrule" valign="top">Nevirapine and telaprevir should not be coadministered because changes in plasma concentrations of nevirapine, telaprevir, or both may result in a reduction in telaprevir efficacy or an increase in nevirapine-associated adverse events.<br>
</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" colspan="3" valign="top">
<span class="Bold">Other Agents</span><br>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Analgesics:</span><br>Methadone* <br>
</td>
<td class="Rrule" valign="top"> <br>↓Methadone<br>
</td>
<td class="Rrule" valign="top"> <br>Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone-maintained patients beginning nevirapine therapy should be monitored for evidence of withdrawal and methadone dose should be adjusted accordingly.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Antiarrhythmics:</span><br>Amiodarone, disopyramide, lidocaine<br>
</td>
<td class="Rrule" valign="top"> <br>Plasma concentrations may be decreased. <br>
</td>
<td class="Rrule" valign="top"> <br>Appropriate doses for this combination have not been established.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Antibiotics:</span><br>Clarithromycin*<br>
</td>
<td class="Rrule" valign="top"> <br>↓Clarithromycin<br>↑14-OH clarithromycin <br>
</td>
<td class="Rrule" valign="top"> <br>Clarithromycin exposure was significantly decreased by nevirapine; however, 14-OH metabolite concentrations were increased. Because clarithromycin active metabolite has reduced activity against <span class="Italics">Mycobacterium avium- intracellulare complex</span>, overall activity against this pathogen may be altered. Alternatives to clarithromycin, such as azithromycin, should be considered.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Rifabutin*<br>
</td>
<td class="Rrule" valign="top">↑Rifabutin<br>
</td>
<td class="Rrule" valign="top">Rifabutin and its metabolite concentrations were moderately increased. Due to high intersubject variability, however, some patients may experience large increases in rifabutin exposure and may be at higher risk for rifabutin toxicity. Therefore, caution should be used in concomitant administration.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Rifampin*<br>
</td>
<td class="Rrule" valign="top">↓Nevirapine<br>
</td>
<td class="Rrule" valign="top">Nevirapine and rifampin should not be administered concomitantly because decreases in nevirapine plasma concentrations may reduce the efficacy of the drug. Physicians needing to treat patients co-infected with <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> and using a nevirapine-containing regimen may use rifabutin instead.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Anticonvulsants:</span><br>Carbamazepine, clonazepam, ethosuximide <br>
</td>
<td class="Rrule" valign="top"> <br>Plasma concentrations of nevirapine and the anticonvulsant may be decreased.<br>
</td>
<td class="Rrule" valign="top"> <br>Use with caution and monitor virologic response and levels of anticonvulsants.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Antifungals:</span><br>Fluconazole*<br>
</td>
<td class="Rrule" valign="top"> <br>↑Nevirapine<br>
</td>
<td class="Rrule" valign="top"> <br>Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Ketoconazole*<br>
</td>
<td class="Rrule" valign="top">↓Ketoconazole<br>
</td>
<td class="Rrule" valign="top">Nevirapine and ketoconazole should not be administered concomitantly because decreases in ketoconazole plasma concentrations may reduce the efficacy of the drug.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Itraconazole<br>
</td>
<td class="Rrule" valign="top">↓Itraconazole<br>
</td>
<td class="Rrule" valign="top">Nevirapine and itraconazole should not be administered concomitantly due to potential decreases in itraconazole plasma concentrations that may reduce efficacy of the drug.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Antithrombotics:</span><br>Warfarin <br>
</td>
<td class="Rrule" valign="top"> <br>Plasma concentrations may be increased.<br>
</td>
<td class="Rrule" valign="top"> <br>Potential effect on anticoagulation. Monitoring of anticoagulation levels is recommended.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Calcium channel blockers:</span><br>Diltiazem, nifedipine, verapamil<br>
</td>
<td class="Rrule" valign="top"> <br>Plasma concentrations may be decreased.<br>
</td>
<td class="Rrule" valign="top"> <br>Appropriate doses for these combinations have not been established.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Cancer chemotherapy:</span><br>Cyclophosphamide<br>
</td>
<td class="Rrule" valign="top"> <br>Plasma concentrations may be decreased.<br>
</td>
<td class="Rrule" valign="top"> <br>Appropriate doses for this combination have not been established.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Ergot alkaloids:</span><br>Ergotamine<br>
</td>
<td class="Rrule" valign="top"> <br>Plasma concentrations may be decreased.<br>
</td>
<td class="Rrule" valign="top"> <br>Appropriate doses for this combination have not been established.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Immunosuppressants:</span><br>Cyclosporine, tacrolimus, sirolimus <br>
</td>
<td class="Rrule" valign="top"> <br>Plasma concentrations may be decreased.<br>
</td>
<td class="Rrule" valign="top"> <br>Appropriate doses for these combinations have not been established.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Motility agents:</span><br>Cisapride<br>
</td>
<td class="Rrule" valign="top"> <br>Plasma concentrations may be decreased.<br>
</td>
<td class="Rrule" valign="top"> <br>Appropriate doses for this combination have not been established.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Opiate agonists:</span><br>Fentanyl<br>
</td>
<td class="Rrule" valign="top"> <br>Plasma concentrations may be decreased.<br>
</td>
<td class="Rrule" valign="top"> <br>Appropriate doses for this combination have not been established.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Oral contraceptives:</span><br>Ethinyl estradiol and Norethindrone*<br>
</td>
<td class="Rrule" valign="top"> <br>↓Ethinyl estradiol<br>↓Norethindrone<br>
</td>
<td class="Rrule" valign="top"> <br>Oral contraceptives and other hormonal methods of birth control should not be used as the sole method of contraception in women taking nevirapine, since nevirapine may lower the plasma levels of these medications. An alternative or additional method of contraception is recommended.<br>
</td>
</tr>
<tr class="Last"><td class="Lrule Rrule" colspan="3" valign="top">* The interaction between nevirapine and the drug was evaluated in a clinical study. All other drug interactions shown are predicted.<br>
</td></tr>
</tbody>
</table>
<br>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<br><p class="First"><span class="Italics"><span class="Bold">Teratogenic Effects<br><br>Pregnancy Category B</span></span><br><br>There are no adequate and well-controlled trials of nevirapine in pregnant women. The Antiretroviral Pregnancy Registry, which has been surveying pregnancy outcomes since January 1989, has not found an increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> following first trimester exposures to nevirapine. The prevalence of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> after any trimester exposure to nevirapine is comparable to the prevalence observed in the general population.<br><br>Severe hepatic events, including fatalities, have been reported in pregnant women receiving chronic nevirapine therapy as part of combination treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Regardless of pregnancy status, women with CD4<span class="Sup">+</span> cell counts greater than 250 cells/mm<span class="Sup">3</span> should not initiate nevirapine unless the benefit outweighs the risk. It is unclear if pregnancy augments the risk observed in non-pregnant women <span class="Italics">[see <a href="#Section_0">Boxed Warning</a>]</span>.<br><br>Nevirapine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.<br><br><span class="Italics">A</span><span class="Italics">ntiretroviral Pregnancy Registry <br></span><br>To monitor maternal-fetal outcomes of pregnant women exposed to nevirapine, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling (800) 258-4263.<br><span class="Bold"><span class="Italics"><br>Animal Data<br></span></span><br>No observable <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was detected in reproductive studies performed in pregnant rats and rabbits. The maternal and developmental no-observable-effect level dosages produced systemic exposures approximately equivalent to or approximately 50% higher in rats and rabbits, respectively, than those seen at the recommended daily human dose (based on AUC). In rats, decreased fetal body weights were observed due to administration of a maternally toxic dose (exposures approximately 50% higher than that seen at the recommended human clinical dose).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<br><p class="First"><span class="Bold">The Centers for Disease Control and Prevention recommend that HIV-1 infected mothers not breast-feed their infants to avoid risking postnatal transmission of </span><span class="Bold">HIV-1.</span><span class="Bold"> Nevirapine is excreted in breast milk. Because of both the potential for HIV-1 transmission and the potential for serious adverse reactions in nursing infants, mothers should be instructed not to breast-feed if they are receiving nevirapine.</span></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<br><p class="First">The safety, pharmacokinetic profile, and virologic and immunologic responses of nevirapine have been evaluated in HIV-1 infected pediatric subjects age 3 months to 18 years <span class="Italics">[see <a href="#Section_6.2">Adverse Reactions (6.2)</a> and <a href="#Section_14.2">Clinical Studies (14.2)</a>]</span>. </p>
<span class="Italics"></span><p>The safety and pharmacokinetic profile of nevirapine has been evaluated in HIV-1 infected pediatric subjects age 15 days to less than 3 months <span class="Italics">[see <a href="#Section_6.2">Adverse Reactions (6.2)</a> and <a href="#Section_14.2">Clinical Studies (14.2)</a>]</span>.<br><br>The most frequently reported adverse events related to nevirapine in pediatric subjects were similar to those observed in adults, with the exception of <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, which was more commonly observed in children receiving both zidovudine and nevirapine <span class="Italics">[see <a href="#Section_6.2">Adverse Reactions (6.2)</a> and <span class="Italics"><a href="#Section_14.2">Clinical Studies  (14.2)</a></span></span><span class="Italics">]</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<br><p class="First">Clinical trials of nevirapine did not include sufficient numbers of subjects aged 65 and older to determine whether elderly subjects respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<br><p class="First">In subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (mild, moderate or severe), there were no significant changes in the pharmacokinetics of nevirapine. Nevirapine is extensively metabolized by the liver and nevirapine metabolites are extensively eliminated by the kidney. Nevirapine metabolites may accumulate in patients receiving dialysis; however, the clinical significance of this accumulation is not known. No adjustment in nevirapine dosing is required in patients with CrCL greater than or equal to 20 mL per min. The pharmacokinetics of nevirapine have not been evaluated in patients with CrCl less than 20 mL per min. In patients undergoing chronic hemodialysis, an additional 200 mg dose following each dialysis treatment is indicated <span class="Italics">[see <a href="#Section_2.4">Dosage and Administration (2.4)</a> and <span class="Italics"><a href="#Section_12.3">Clinical  Pharmacology (12.3)</a></span></span><span class="Italics">]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<br><p class="First">Because increased nevirapine levels and nevirapine accumulation may be observed in patients with serious liver disease, do not administer nevirapine to patients with moderate or severe (Child-Pugh Class B or C, respectively) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#Section_4.1">Contraindications (4.1)</a>, <a href="#Section_5.1">Warnings and Precautions (5.1)</a>, and <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<br><p class="First">There is no known antidote for nevirapine overdosage. Cases of nevirapine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> at doses ranging from 800 to 1800 mg per day for up to 15 days have been reported. Patients have experienced events including <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">erythema nodosum</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, pulmonary infiltrates, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>. All events subsided following discontinuation of nevirapine.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<br><p class="First">Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with activity against Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus Type 1 (HIV-1). Nevirapine is structurally a member of the dipyridodiazepinone chemical class of compounds.<br><br>The chemical name of nevirapine is 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido [3,2-b:2',3'-e][1,4] diazepin-6-one. Nevirapine USP is a white to off-white crystalline powder with the molecular weight of 266.30 and the molecular formula C<span class="Sub">15</span>H<span class="Sub">14</span>N<span class="Sub">4</span>O. Nevirapine has the following structural formula:</p>
<br><div class="Figure"><img alt="chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8dfe86aa-ea5d-48d2-94a8-1a5506055d70&amp;name=nevirapine-str.jpg"></div>
<br><p>Nevirapine oral suspension, USP is for oral administration. Each 5 mL of nevirapine oral suspension contains 50 mg of nevirapine (as nevirapine hemihydrate). The suspension also contains the following excipients: carbopol 974PNF, methylparaben, propylparaben, non crystallizing sorbitol solution, sucrose, propylene glycol, polysorbate 80, sodium hydroxide, and purified water.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<br><p class="First">Nevirapine is an antiviral drug <span class="Italics">[see <a href="#Section_12.4">Microbiology (12.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<br><p class="First"><span class="Italics"><span class="Bold">Adults</span></span><br><br><span class="Underline">Absorption and Bioavailability </span><br><br>Nevirapine is readily absorbed (greater than 90%) after oral administration in healthy volunteers and in adults with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Absolute bioavailability in 12 healthy adults following single-dose administration was 93 ± 9% (mean ± SD) for a 50 mg tablet and 91 ± 8% for an oral solution. Peak plasma nevirapine concentrations of 2 ± 0.4 mcg/mL (7.5 micromolar) were attained by 4 hours following a single 200 mg dose. Following multiple doses, nevirapine peak concentrations appear to increase linearly in the dose range of 200 to 400 mg/day. Steady-state trough nevirapine concentrations of 4.5 ± 1.9 mcg/mL (17 ± 7 micromolar), (n=242) were attained at 400 mg per day. Nevirapine tablets and suspension have been shown to be comparably bioavailable and interchangeable at doses up to 200 mg. When nevirapine (200 mg) was administered to 24 healthy adults (12 female, 12 male), with either a high-fat breakfast (857 kcal, 50 g fat, 53% of calories from fat) or antacid (Maalox<span class="Sup">®</span> 30 mL), the extent of nevirapine absorption (AUC) was comparable to that observed under fasting conditions. In a separate trial in HIV-1 infected subjects (n=6), nevirapine steady-state systemic exposure (AUC<span class="Sub">τ</span>) was not significantly altered by didanosine, which is formulated with an alkaline buffering agent. Nevirapine may be administered with or without food, antacid or didanosine.<br><br><span class="Underline">Distribution </span><br><br>Nevirapine is highly lipophilic and is essentially nonionized at physiologic pH. Following intravenous administration to healthy adults, the apparent volume of distribution (Vdss) of nevirapine was 1.21 ± 0.09 L/kg, suggesting that nevirapine is widely distributed in humans. Nevirapine readily crosses the placenta and is also found in breast milk <span class="Italics">[see <a href="#Section_8.3">Use in Specific Populations (8.3)</a>]</span>. Nevirapine is about 60% bound to plasma proteins in the plasma concentration range of 1 to 10 mcg per mL. Nevirapine concentrations in human cerebrospinal fluid (n=6) were 45% (± 5%) of the concentrations in plasma; this ratio is approximately equal to the fraction not bound to plasma protein.<br><br><span class="Underline">Metabolism/Elimination </span><br><br><span class="Italics">In vivo </span>trials in humans and <span class="Italics">in vitro </span>studies with human liver microsomes have shown that nevirapine is extensively biotransformed via cytochrome P450 (oxidative) metabolism to several hydroxylated metabolites. <span class="Italics">In vitro </span>studies with human liver microsomes suggest that oxidative metabolism of nevirapine is mediated primarily by cytochrome P450 (CYP) isozymes from the CYP3A and CYP2B6 families, although other isozymes may have a secondary role. In a <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance/excretion trial in eight healthy male volunteers dosed to steady state with nevirapine 200 mg given twice daily followed by a single 50 mg dose of <span class="Sup">14</span>C-nevirapine, approximately 91.4 ± 10.5% of the radiolabeled dose was recovered, with urine (81.3 ± 11.1%) representing the primary route of excretion compared to feces (10.1 ± 1.5%). Greater than 80% of the radioactivity in urine was made up of glucuronide conjugates of hydroxylated metabolites. Thus cytochrome P450 metabolism, glucuronide conjugation, and urinary excretion of glucuronidated metabolites represent the primary route of nevirapine biotransformation and elimination in humans. Only a small fraction (less than 5%) of the radioactivity in urine (representing less than 3% of the total dose) was made up of parent compound; therefore, renal excretion plays a minor role in elimination of the parent compound.<br><br>Nevirapine is an inducer of hepatic cytochrome P450 (CYP) metabolic enzymes 3A and 2B6. Nevirapine induces CYP3A and CYP2B6 by approximately 20 to 25%, as indicated by erythromycin breath test results and urine metabolites. Autoinduction of CYP3A and CYP2B6 mediated metabolism leads to an approximately 1.5- to 2-fold increase in the apparent oral clearance of nevirapine as treatment continues from a single dose to two-to-four weeks of dosing with 200 to 400 mg per day. Autoinduction also results in a corresponding decrease in the terminal phase half-life of nevirapine in plasma, from approximately 45 hours (single dose) to approximately 25 to 30 hours following multiple dosing with 200 to 400 mg per day.<br><br><span class="Italics"><span class="Bold">Specific </span></span><span class="Italics"><span class="Bold">Populations</span></span><br><br><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </span><br><br>HIV-1 seronegative adults with mild (CrCL 50 to 79 mL per min; n=7), moderate (CrCL 30 to 49 mL per min; n=6), or severe (CrCL less than 30 mL per min; n=4) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> received a single  200 mg dose of nevirapine in a pharmacokinetic trial. These subjects did not require dialysis. The trial included six additional subjects with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> requiring dialysis.<br><br>In subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (mild, moderate or severe), there were no significant changes in the pharmacokinetics of nevirapine. However, subjects requiring dialysis exhibited a 44% reduction in nevirapine AUC over a one-week exposure period. There was also evidence of accumulation of nevirapine hydroxy-metabolites in plasma in subjects requiring dialysis. An additional 200 mg dose following each dialysis treatment is indicated <span class="Italics">[see <a href="#Section_2.4">Dosage and Administration (2.4)</a> and <a href="#Section_8.6">Use in Specific Populations (8.6)</a>]</span>.<br><br><span class="Underline"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span><br><br>In a steady-state trial comparing 46 subjects with mild (n=17; expansion of some portal areas; Ishak Score 1 to 2), moderate (n=20; expansion of most portal areas with occasional portal-to-portal and portal-to-central bridging; Ishak Score 3 to 4), or severe (n=9; marked bridging with occasional cirrhosis without decompensation indicating Child-Pugh A; Ishak Score 5 to 6) <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> as a measure of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, the multiple dose pharmacokinetic disposition of nevirapine and its five oxidative metabolites were not altered. However, approximately 15% of these subjects with <span class="product-label-link" type="condition" conceptid="4267417" conceptname="Hepatic fibrosis">hepatic fibrosis</span> had nevirapine trough concentrations above 9,000 mcg per mL (2-fold the usual mean trough). Therefore, patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should be monitored carefully for evidence of drug-induced toxicity <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span>. </p>
<span class="Italics"></span><p>The subjects studied were receiving antiretroviral therapy containing nevirapine 200 mg twice daily for at least 6 weeks prior to pharmacokinetic sampling, with a median duration of therapy of 3.4 years.<br><br>In a pharmacokinetic trial where HIV-1 negative cirrhotic subjects with mild (Child-Pugh A; n=6) or moderate (Child-Pugh B; n=4) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> received a single 200 mg dose of nevirapine, a significant increase in the AUC of nevirapine was observed in one subject with Child-Pugh B and <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> suggesting that patients with worsening hepatic function and <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> may be at risk of accumulating nevirapine in the systemic circulation. Because nevirapine induces its own metabolism with multiple dosing, this single-dose trial may not reflect the impact of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on multiple-dose pharmacokinetics.<br><br>Do not administer nevirapine to patients with moderate or severe (Child-Pugh Class B or C, respectively) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#Section_4">Contraindications (4)</a>, <span class="Italics"><a href="#Section_5.1">Warnings  and Precautions (5.1)</a></span></span><span class="Italics">, and <span class="Italics"><a href="#Section_8.7">Use in Specific Populations (8.7)</a></span>]</span>.<br><br><span class="Underline">Gender </span><br><br>In the multinational 2NN trial, a population pharmacokinetic substudy of 1077 subjects was performed that included 391 females. Female subjects showed a 13.8% lower clearance of nevirapine than did men. Since neither body weight nor Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> Index (BMI) had an influence on the clearance of nevirapine, the effect of gender cannot solely be explained by body size.<br><br><span class="Underline">Race </span><br><br>An evaluation of nevirapine plasma concentrations (pooled data from several clinical trials) from HIV-1-infected subjects (27 Black, 24 Hispanic, 189 Caucasian) revealed no marked difference in nevirapine steady-state trough concentrations (median C<span class="Sub">minss </span><span class="Italics">= </span>4.7 mcg/mL Black, 3.8 mcg/mL Hispanic, 4.3 mcg/mL Caucasian) with long-term nevirapine treatment at 400 mg per day. However, the pharmacokinetics of nevirapine have not been evaluated specifically for the effects of ethnicity.<br><br>Black subjects (n=80/group) in Trial 1100.1486 showed approximately 30% to 35% higher trough concentrations than Caucasian subjects (250 to 325 subjects/group) in both immediate-release nevirapine and nevirapine extended-release treatment groups over 96 weeks of treatment at 400 mg per day.<br><span class="Underline"><br>Geriatric Subjects </span><br><br>Nevirapine pharmacokinetics in HIV-1-infected adults do not appear to change with age (range 18 to 68 years); however, nevirapine has not been extensively evaluated in subjects beyond the age of 55 years <span class="Italics">[see <span class="Italics"><a href="#Section_8.5">Use in Specific Populations (8.5)</a></span>]</span>.<br><br><span class="Underline">Pediatric Subjects </span><br><br>Pharmacokinetic data for nevirapine have been derived from two sources: a 48-week pediatric trial in South Africa (BI Trial 1100.1368) involving 123 HIV-1 positive, antiretroviral-naïve subjects aged 3 months to 16 years; and a consolidated analysis of five Pediatric AIDS Clinical Trials Group (PACTG) protocols comprising 495 subjects aged 14 days to 19 years.<br><br>BI Trial 1100.1368 studied the safety, efficacy, and pharmacokinetics of a weight-based and a body surface area (BSA)-based dosing regimen of nevirapine. In the weight-based regimen, pediatric subjects up to 8 years of age received a dose of 4 mg/kg once daily for two weeks followed by 7 mg per kg twice daily thereafter. Subjects 8 years and older were dosed 4 mg/kg once daily for two weeks followed by 4 mg/kg twice daily thereafter. In the BSA regimen, all pediatric subjects received 150 mg/m<span class="Sup">2</span> once daily for two weeks followed by 150 mg/m<span class="Sup">2</span> twice daily thereafter <span class="Italics">[see <span class="Italics"><a href="#Section_8.4">Use in Specific Populations (8.4)</a></span> and <span class="Italics"><a href="#Section_6.2">Adverse Reactions (6.2)</a></span>]</span>. </p>
<span class="Italics"></span><p>Dosing of nevirapine at 150 mg/m<span class="Sup">2</span> BID (after a two-week lead-in of 150 mg/m<span class="Sup">2</span> QD) produced geometric mean or mean trough nevirapine concentrations between 4 to 6 mcg per mL (as targeted from adult data). In addition, the observed trough nevirapine concentrations were comparable between the two dosing regimens studied (BSA- and weight-based methods).<br><br>The consolidated analysis of Pediatric AIDS Clinical Trials Group (PACTG) protocols 245, 356, 366, 377, and 403 allowed for the evaluation of pediatric subjects less than 3 months of age (n=17). The plasma nevirapine concentrations observed were within the range observed in adults and the remainder of the pediatric population, but were more variable between subjects, particularly in the second month of age. For dose recommendations for pediatric patients <span class="Italics">[see </span><span class="Italics"><span class="Italics"><a href="#Section_2.2">Dosage and Administration  (2.2)</a></span></span><span class="Italics">].</span><br><br><span class="Italics"><span class="Bold">Drug Interactions [see </span><span class="Italics"><span class="Bold"><a href="#Section_7">Drug Interactions (7)</a></span></span><span class="Bold">]</span></span><br><br>Nevirapine induces hepatic cytochrome P450 metabolic isoenzymes 3A and 2B6. Co-administration of nevirapine and drugs primarily metabolized by CYP3A or CYP2B6 may result in decreased plasma concentrations of these drugs and attenuate their therapeutic effects.<br><br>While primarily an inducer of cytochrome P450 3A and 2B6 enzymes, nevirapine may also inhibit this system. Among human hepatic cytochrome P450s, nevirapine was capable <span class="Italics">in vitro </span>of inhibiting the 10-hydroxylation of (R)-warfarin (CYP3A). The estimated K<span class="Sub">i</span> for the inhibition of CYP3A was 270 micromolar, a concentration that is unlikely to be achieved in patients as the therapeutic range is less than 25 micromolar. Therefore, nevirapine may have minimal inhibitory effect on other substrates of CYP3A.<br><br>Nevirapine does not appear to affect the plasma concentrations of drugs that are substrates of other CYP450 enzyme systems, such as 1A2, 2D6, 2A6, 2E1, 2C9, or 2C19.<br><br>Table 5 (see below) contains the results of drug interaction trials performed with nevirapine and other drugs likely to be co-administered. The effects of nevirapine on the AUC, C<span class="Sub">max</span>, and C<span class="Sub">min</span> of co-administered drugs are summarized.</p>
<br><table border="0" cellpadding="0" cellspacing="0" width="693">
<caption><span>Table 5 Drug Interactions: Changes in Pharmacokinetic Parameters for Co-administered Drug in the Presence of Nevirapine (All interactions trials were conducted in HIV-1 positive subjects) 
			</span></caption>
<thead>
<tr class="First">
<th class="Lrule Rrule Toprule">Co-administered Drug </th>
<th class="Lrule Rrule Toprule">Dose of <br>            Co-administered Drug </th>
<th class="Lrule Rrule Toprule" colspan="2">Dose Regimen of<br>            Nevirapine </th>
<th class="Lrule Rrule Toprule" align="center">n </th>
<th class="Lrule Rrule Toprule" align="center" colspan="5">% Change of Co-administered Drug<br>            Pharmacokinetic Parameters (90% CI)</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule Toprule" align="center">Antiretrovirals</th>
<th class="Lrule Rrule Toprule" align="center"></th>
<th class="Lrule Rrule Toprule" align="center" colspan="2"></th>
<th class="Lrule Rrule Toprule" align="center"></th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">AUC</th>
<th class="Lrule Rrule Toprule" align="center" colspan="2">C<span class="Sub">max</span>
</th>
<th class="Lrule Rrule Toprule" align="center">C<span class="Sub">min</span>
</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td colspan="10">§ = C<span class="Sub">min</span> below detectable level of the assay<br>↑ = Increase, ↓<span class="Italics">= </span>Decrease, ↔ = No Effect<br><span class="Sup">a </span>For information regarding clinical recommendations, see <span class="Italics"><span class="Italics"><span class="Bold"><a href="#Section_7">Drug Interactions (7)</a></span></span>.</span><br><span class="Sup">b </span>Pediatric subjects ranging in age from 6 months to 12 years.<br><span class="Sup">c </span>Parallel group design; n for nevirapine+lopinavir/ritonavir, n for lopinavir/ritonavir alone.<br><span class="Sup">d </span>Parallel group design; n=23 for atazanavir/ritonavir + nevirapine, n=22 for atazanavir/ritonavir without nevirapine. Changes in atazanavir<br>            PK are relative to atazanavir/ritonavir 300/100 mg alone. <br><span class="Sup">e </span>Based on between-trial comparison. <br><span class="Sup">f </span>Based on historical controls.<br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" rowspan="2" valign="top">Atazanavir/Ritonavir<span class="Sup">a,d</span><br>
</td>
<td class="Rrule" rowspan="2" valign="top">300/100 mg QD day<br>            4 to 13, then 400/100 mg<br>QD, day 14 to 23<br>
</td>
<td class="Rrule" colspan="2" rowspan="2" valign="top">200 mg BID day 1 to 23.<br>            Subjects were treated with<br>nevirapine prior to trial entry.<br>
</td>
<td class="Rrule" align="center" rowspan="2" valign="top"> <br>23<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">Atazanavir<br>            300/100 mg<br>↓42<br>            (↓52 to ↓29)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">Atazanavir<br>            300/100 mg<br> <br>↓28<br>            (↓40 to ↓14)<br>
</td>
<td class="Rrule" align="center" valign="top">Atazanavir<br>            300/100 mg<br> <br>↓72<br>            (↓80 to ↓60)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" colspan="2" valign="top">Atazanavir<br>            400/100 mg<br>            ↓19<br>            (↓35 to ↑2)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">Atazanavir<br>            400/100 mg<br>            ↑2<br>            (↓15 to ↑24)<br>
</td>
<td class="Rrule" align="center" valign="top">Atazanavir<br>            400/100 mg<br>            ↓59<br>            (↓73 to ↓40)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Darunavir/Ritonavir<span class="Sup">e</span><br>
</td>
<td class="Rrule" valign="top">400/100 mg BID<br>
</td>
<td class="Rrule" colspan="2" valign="top">200 mg BID<br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↑24<br>            (↓3 to ↑57)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↑40<br>            (↑14 to ↑73)<br>
</td>
<td class="Rrule" align="center" valign="top">↑2<br>            (↓21 to ↑32)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Didanosine <br>
</td>
<td class="Rrule" valign="top">100 to 150 mg BID <br>
</td>
<td class="Rrule" colspan="2" valign="top">200 mg QD x 14 days;<br>            200 mg BID x 14 days <br>
</td>
<td class="Rrule" align="center" valign="top">18<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↔<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↔<br>
</td>
<td class="Rrule" align="center" valign="top">§<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Efavirenz<span class="Sup">a</span><br>
</td>
<td class="Rrule" valign="top">600 mg QD<br>
</td>
<td class="Rrule" colspan="2" valign="top">200 mg QD x 14 days;<br>            400 mg QD x 14 days<br>
</td>
<td class="Rrule" align="center" valign="top">17<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↓28<br>            (↓34 to ↓14)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↓12<br>            (↓23 to ↑1)<br>
</td>
<td class="Rrule" align="center" valign="top">↓32<br>            (↓35 to ↓19)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Fosamprenavir<br>
</td>
<td class="Rrule" valign="top">1400 mg BID<br>
</td>
<td class="Rrule" colspan="2" valign="top">200 mg BID.<br>            Subjects were treated with<br>nevirapine prior to trial entry.<br>
</td>
<td class="Rrule" align="center" valign="top">17<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↓33<br>            (↓45 to ↓20)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↓25<br>            (↓37 to ↓10)<br>
</td>
<td class="Rrule" align="center" valign="top">↓35<br>            (↓50 to ↓15)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Fosamprenavir/Ritonavir<br>
</td>
<td class="Rrule" valign="top">700/100 mg BID<br>
</td>
<td class="Rrule" colspan="2" valign="top">200 mg BID.<br>            Subjects were treated with<br>nevirapine prior to trial entry<br>
</td>
<td class="Rrule" align="center" valign="top">17<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↓11<br>            (↓23 to ↑3)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↔<br>
</td>
<td class="Rrule" align="center" valign="top">↓19<br>            (↓32 to ↓4)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Indinavir<span class="Sup">a </span><br>
</td>
<td class="Rrule" valign="top">800 mg q8H <br>
</td>
<td class="Rrule" colspan="2" valign="top">200 mg QD x 14 days;<br>            200 mg BID x 14 days<br>
</td>
<td class="Rrule" align="center" valign="top">19<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↓31<br>            (↓39 to ↓22)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↓15<br>            (↓24 to ↓4)<br>
</td>
<td class="Rrule" align="center" valign="top">↓44<br>            (↓53 to ↓33)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Lopinavir<span class="Sup">a, b</span><br>
</td>
<td class="Rrule" valign="top">300/75 mg/m<span class="Sup">2 </span><br>            (lopinavir/ ritonavir)<span class="Sup">b</span><br>
</td>
<td class="Rrule" colspan="2" valign="top">7 mg/kg or 4 mg/kg <br>            QD x 2 weeks;<br>BID x 1 week <br>
</td>
<td class="Rrule" align="center" valign="top">12, 15<span class="Sup">c</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↓22<br>            (↓44 to ↑9)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↓14<br>            (↓36 to ↑16)<br>
</td>
<td class="Rrule" align="center" valign="top">↓55<br>            (↓75 to ↓19)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Lopinavir<span class="Sup">a </span><br>
</td>
<td class="Rrule" valign="top">400/100 mg BID<br>            (lopinavir/ ritonavir) <br>
</td>
<td class="Rrule" colspan="2" valign="top">200 mg QD x 14 days;<br>            200 mg BID &gt;1 year<br>
</td>
<td class="Rrule" align="center" valign="top">22, 19<span class="Sup">c</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↓27<br>            (↓47 to ↓2)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↓19<br>            (↓38 to ↑5)<br>
</td>
<td class="Rrule" align="center" valign="top">↓51<br>            (↓72 to ↓26)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Maraviroc<span class="Sup">f</span><br>
</td>
<td class="Rrule" valign="top">300 mg SD<br>
</td>
<td class="Rrule" colspan="2" valign="top">200 mg BID<br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↑1<br>            (↓35 to ↑55)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↑54<br>            (↓6 to ↑151)<br>
</td>
<td class="Rrule" align="center" valign="top">↔<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="2" valign="top">Nelfinavir<span class="Sup">a </span><br>Nelfinavir-M8 metabolite <br>
</td>
<td class="Rrule" rowspan="2" valign="top">750 mg TID <br>
</td>
<td class="Rrule" colspan="2" rowspan="2" valign="top">200 mg QD x 14 days;<br>            200 mg BID x 14 days <br>
</td>
<td class="Rrule" align="center" rowspan="2" valign="top">23<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↔<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↔<br>
</td>
<td class="Rrule" align="center" valign="top">↓32<br>            (↓50 to ↑5)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" colspan="2" valign="top">↓62<br>            (↓70 to ↓53)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↓59<br>            (↓68 to ↓48)<br>
</td>
<td class="Rrule" align="center" valign="top">↓66<br>            (↓74 to ↓55)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Ritonavir <br>
</td>
<td class="Rrule" valign="top">600 mg BID <br>
</td>
<td class="Rrule" colspan="2" valign="top">200 mg QD x 14 days;<br>            200 mg BID x 14 days <br>
</td>
<td class="Rrule" align="center" valign="top">18<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↔<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↔<br>
</td>
<td class="Rrule" align="center" valign="top">↔<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Stavudine <br>
</td>
<td class="Rrule" valign="top">30 to 40 mg BID <br>
</td>
<td class="Rrule" colspan="2" valign="top">200 mg QD x 14 days;<br>            200 mg BID x 14 days <br>
</td>
<td class="Rrule" align="center" valign="top">22<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↔<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↔<br>
</td>
<td class="Rrule" align="center" valign="top">§<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Zalcitabine <br>
</td>
<td class="Rrule" valign="top">0.125 to 0.25 mg TID <br>
</td>
<td class="Rrule" colspan="2" valign="top">200 mg QD x 14 days;<br>            200 mg BID x 14 days <br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↔<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↔<br>
</td>
<td class="Rrule" align="center" valign="top">§<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Zidovudine<br>
</td>
<td class="Rrule" valign="top">100 to 200 mg TID<br>
</td>
<td class="Rrule" colspan="2" valign="top">200 mg QD x 14 days;<br>            200 mg BID x 14 days<br>
</td>
<td class="Rrule" align="center" valign="top">11<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↓28<br>            (↓40 to ↓4)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↓30<br>            (↓51 to ↑14)<br>
</td>
<td class="Rrule" align="center" valign="top">§<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">
<span class="Bold">Other Medications </span><br>
</td>
<td class="Rrule" valign="top"> <br>
</td>
<td class="Rrule" colspan="2" valign="top"> <br>
</td>
<td class="Rrule" valign="top"> <br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">AUC</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">C<span class="Sub">max</span></span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">C<span class="Sub">min</span></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="2" valign="top">Clarithromycin<span class="Sup">a</span><br>Metabolite<br>            14-OH-clarithromycin <br>
</td>
<td class="Rrule" colspan="2" rowspan="2" valign="top">500 mg BID<br>
</td>
<td class="Rrule" rowspan="2" valign="top">200 mg QD x 14 days;<br>            200 mg BID x 14 days<br>
</td>
<td class="Rrule" align="center" rowspan="2" valign="top">15<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↓31<br>            (↓38 to ↓24)<br>
</td>
<td class="Rrule" align="center" valign="top">↓23<br>            (↓31 to ↓14)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↓56<br>            (↓70 to ↓36)<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" colspan="2" valign="top">↑42<br>            (↑16 to ↑73)<br>
</td>
<td class="Rrule" align="center" valign="top">↑47<br>            (↑21 to ↑80)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↔<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="2" valign="top">Ethinyl estradiol<span class="Sup">a </span>and <br>Norethindrone<span class="Sup">a</span><br>
</td>
<td class="Rrule" colspan="2" rowspan="2" valign="top">0.035 mg<br>            (as Ortho-Novum® 1/35) <br>1 mg<br>            (as Ortho-Novum® 1/35)<br>
</td>
<td class="Rrule" rowspan="2" valign="top">200 mg QD x 14 days;<br>            200 mg BID x 14 days<br>
</td>
<td class="Rrule" align="center" rowspan="2" valign="top">10<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↓20<br>            (↓33 to ↓3)<br>
</td>
<td class="Rrule" align="center" valign="top">↔<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">§<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" colspan="2" valign="top">↓19<br>            (↓30 to ↓7)<br>
</td>
<td class="Rrule" align="center" valign="top">↓16<br>            (↓27 to ↓3)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">§<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Depomedroxy-<br>            progesterone acetate<br>
</td>
<td class="Rrule" colspan="2" valign="top">150 mg every 3 months<br>
</td>
<td class="Rrule" valign="top">200 mg QD x 14 days;<br>            200 mg BID x 14 days<br>
</td>
<td class="Rrule" align="center" valign="top">32<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↔<br>
</td>
<td class="Rrule" align="center" valign="top">↔<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↔<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Fluconazole<br>
</td>
<td class="Rrule" colspan="2" valign="top">200 mg QD<br>
</td>
<td class="Rrule" valign="top">200 mg QD x 14 days;<br>            200 mg BID x 14 days<br>
</td>
<td class="Rrule" align="center" valign="top">19<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↔<br>
</td>
<td class="Rrule" align="center" valign="top">↔<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↔<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Ketoconazole<span class="Sup">a </span><br>
</td>
<td class="Rrule" colspan="2" valign="top">400 mg QD <br>
</td>
<td class="Rrule" valign="top">200 mg QD x 14 days;<br>            200 mg BID x 14 days<br>
</td>
<td class="Rrule" align="center" valign="top">21<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↓72<br>            (↓80 to ↓60)<br>
</td>
<td class="Rrule" align="center" valign="top">↓44<br>            (↓58 to ↓27)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">§<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Methadone<span class="Sup">a</span><br>
</td>
<td class="Rrule" colspan="2" valign="top">Individual Subject Dosing<br>
</td>
<td class="Rrule" valign="top">200 mg QD x 14 days;<br>            200 mg BID ≥7 days<br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
<td class="Rrule" colspan="5" valign="top">In a controlled pharmacokinetic trial with<br>            9 subjects receiving chronic methadone to <br>            whom steady-state nevirapine therapy was<br>            added, the clearance of methadone was <br>            increased by 3-fold, resulting in symptoms <br>            of withdrawal, requiring dose adjustments <br>            in 10 mg segments, in 7 of the 9 subjects. <br>            Methadone did not have any effect on <br>            nevirapine clearance.<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" rowspan="2" valign="top">Rifabutin<span class="Sup">a </span><br>Metabolite<br>            25-O-desacetyl-rifabutin <br>
</td>
<td class="Rrule" colspan="2" rowspan="2" valign="top">150 or 300 mg QD<br> <br>
</td>
<td class="Rrule" rowspan="2" valign="top">200 mg QD x 14 days;<br>            200 mg BID x 14 days<br> <br>
</td>
<td class="Rrule" align="center" rowspan="2" valign="top">19<br> <br>
</td>
<td class="Rrule" align="center" valign="top">↑17<br>            (↓2 to ↑40)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↑28<br>            (↑9 to ↑51)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↔<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">↑24<br>            (↓16 to ↑84)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↑29<br>            (↓2 to ↑68)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↑22<br>            (↓14 to ↑74)<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Rifampin<span class="Sup">a</span><br>
</td>
<td class="Rrule" colspan="2" valign="top">600 mg QD<br>
</td>
<td class="Rrule" valign="top">200 mg QD x 14 days;<br>            200 mg BID x 14 days<br>
</td>
<td class="Rrule" align="center" valign="top">14<br>
</td>
<td class="Rrule" align="center" valign="top">↑11<br>            (↓4 to ↑28)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">↔<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">§<br>
</td>
</tr>
</tbody>
</table>
<p>Because of the design of the drug interaction trials (addition of 28 days of nevirapine therapy to existing HIV-1 therapy), the effect of the concomitant drug on plasma nevirapine steady-state concentrations was estimated by comparison to historical controls.<br><br>Administration of rifampin had a clinically significant effect on nevirapine pharmacokinetics, decreasing AUC and C<span class="Sub">max</span> by greater than 50%. Administration of fluconazole resulted in an approximate 100% increase in nevirapine exposure, based on a comparison to historic data <span class="Italics">[see <span class="Italics"><span class="Bold"><a href="#Section_7">Drug Interactions (7)</a></span></span>]</span>. </p>
<span class="Italics"></span><p>The effect of other drugs listed in Table 5 on nevirapine pharmacokinetics was not significant. No significant interaction was observed when tipranavir was co-administered with low-dose ritonavir and nevirapine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.4"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<br><p class="First"><span class="Italics"><span class="Bold">Mechanism of Action</span></span><br><br>Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1. Nevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates. HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases α, β, γ, or δ) are not inhibited by nevirapine.<br><br><span class="Italics"><span class="Bold">Antiviral Activity</span></span><br><br>The antiviral activity of nevirapine has been measured in a variety of cell lines including peripheral blood mononuclear cells, monocyte-derived macrophages, and lymphoblastoid cell lines. In an assay using human embryonic kidney 293 cells, the median EC<span class="Sub">50</span> value (50% inhibitory concentration) of nevirapine was 90 nM against a panel of 2923 isolates of HIV-1 that were primarily (93%) clade B clinical isolates from the United States. The 99<span class="Sup">th </span>percentile EC<span class="Sub">50</span> value was 470 nM in this trial. The median EC<span class="Sub">50</span> value was 63 nM (range 14 to 302 nM, n=29) against clinical isolates of HIV-1 clades A, B, C, D, F, G, and H, and circulating recombinant forms CRF01_AE, CRF02_AG and CRF12_BF. Nevirapine had no antiviral activity in cell culture against group O HIV-1 isolates (n=3) or HIV-2 isolates (n=3) replicating in cord blood mononuclear cells. Nevirapine in combination with efavirenz exhibited strong antagonistic anti-HIV-1 activity in cell culture and was additive to antagonistic with the protease inhibitor ritonavir or the fusion inhibitor enfuvirtide. Nevirapine exhibited additive to synergistic anti-HIV-1 activity in combination with the protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, saquinavir and tipranavir, and the NRTIs abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir and zidovudine. The anti-HIV-1 activity of nevirapine was antagonized by the anti-HBV drug adefovir and by the anti-HCV drug ribavirin in cell culture.<br><br><span class="Italics"><span class="Bold">Resistance<br></span><br></span>HIV-1 isolates with reduced susceptibility (100- to 250-fold) to nevirapine emerge in cell culture. Genotypic analysis showed mutations in the HIV-1 RT gene encoding Y181C and/or V106A substitutions depending upon the virus <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> and cell line employed. Time to emergence of nevirapine resistance in cell culture was not altered when selection included nevirapine in combination with several other NNRTIs.<br><br>Phenotypic and genotypic changes in HIV-1 isolates from treatment-naïve subjects receiving either nevirapine (n=24) or nevirapine and zidovudine (n=14) were monitored in Phase 1 and 2 trials ranging from1 to 12 weeks or longer. After 1 week of nevirapine monotherapy, isolates from 3/3 subjects had decreased susceptibility to nevirapine in cell culture. One or more of the RT mutations resulting in amino acid substitutions K103N, V106A, V108I, Y181C, Y188C, and G190A were detected in HIV-1 isolates from some subjects as early as 2 weeks after therapy initiation. By week eight of nevirapine monotherapy, 100% of the subjects tested (n=24) had HIV-1 isolates with a greater than 100-fold decrease in susceptibility to nevirapine in cell culture compared to baseline, and had one or more of the nevirapine­-associated RT resistance substitutions. Nineteen of these subjects (80%) had isolates with Y181C substitutions regardless of dose.  <br><br>Genotypic analysis of isolates from antiretroviral-naïve subjects experiencing virologic failure (n=71) receiving nevirapine once daily (n=25) or twice daily (n=46) in combination with lamivudine and stavudine (trial 2NN) for 48 weeks showed that isolates from 8/25 and 23/46 subjects, respectively, contained one or more of the following NNRTI resistance-associated substitutions: Y181C, K101E, G190A/S, K103N, V106A/M, V108I, Y188C/L, A98G, F227L, and M230L.<br><br>For trial 1100.1486, genotypic analysis was performed for baseline and on-therapy isolates from 23 and 34 subjects who experienced virologic failure in the nevirapine extended-release tablets and immediate-release nevirapine treatment group, respectively. Nevirapine resistance-associated substitutions developed in the on-therapy isolates of 78% (18/23) of the subjects who had virologic failures in the nevirapine extended-release tablets treatment group and 88% (30/34) of the subjects in the immediate-release nevirapine treatment group, respectively. The Y181C nevirapine resistance-associated substitution was found alone or in combination with other nevirapine resistance-associated substitutions (K101E, K103N, V106A, V108I, V179D/E/I, Y188 C/F/H/L/N, G190A, P225H, F227L, M230L) in isolates from 14 subjects failing nevirapine extended-release tablets treatment and 25 subjects failing immediate-release nevirapine treatment. On-therapy isolates from 1 subject in nevirapine extended-release tablets treatment group developed a novel amino acid substitution Y181I and isolates from another subject in the immediate-release nevirapine treatment group developed a novel amino acid substitution Y188N. Phenotypic analysis showed that Y188N and Y181I substitutions conferred 103- and 22-fold reductions in susceptibility to nevirapine, respectively.</p>
<br><br><p><span class="Bold"><span class="Italics">Cross-resistance </span></span></p>
<br><p>Rapid emergence of HIV-1 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> which are cross-resistant to NNRTIs has been observed in cell culture. Nevirapine-resistant HIV-1 isolates were cross-resistant to the NNRTIs delavirdine, efavirenz and etravirine.  The Y188N conferred 22- and 7-fold reductions in susceptibility to delavirdine and efavirenz, respectively, but showed no decrease in susceptibility to etravirine. Similarly, the Y181I substitution reduced susceptibility to delavirdine and etravirine 3-and 8-fold, respectively, but did not reduce susceptibility to efavirenz. However, nevirapine-resistant isolates were susceptible to the NRTIs ddI and ZDV. Similarly, ZDV-resistant isolates were susceptible to nevirapine in cell culture.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<br><p class="First"><span class="Bold"><span class="Italics">Carcinogenesis</span></span><br><br>Long<span class="Bold">-</span>term carcinogenicity studies in mice and rats were carried out with nevirapine. Mice were dosed with 0, 50, 375 or 750 mg/kg/day for two years. <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">Hepatocellular adenomas</span> and carcinomas were increased at all doses in males and at the two high doses in females. In studies in which rats were administered nevirapine at doses of 0, 3.5, 17.5 or 35 mg/kg/day for two years, an increase in <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> was seen in males at all doses and in females at the high dose. The systemic exposure (based on AUCs) at all doses in the two animal studies was lower than that measured in humans at the 200 mg twice daily dose. The mechanism of the carcinogenic potential is unknown.<br><span class="Italics"><span class="Bold"><br>Mutagenesis<br></span></span><br>However, in genetic toxicology assays, nevirapine showed no evidence of mutagenic or clastogenic activity in a battery of <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> studies. These included microbial assays for gene mutation (Ames: <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> and <span class="Italics">E. coli</span>), mammalian cell gene mutation assay (CHO/HGPRT), cytogenetic assays using a Chinese hamster ovary cell line and a mouse bone marrow micronucleus assay following oral administration. Given the lack of genotoxic activity of nevirapine, the relevance to humans of hepatocellular neoplasms in nevirapine-treated mice and rats is not known.<br><br><span class="Bold"><span class="Italics">Impairment of Fertility<br></span></span><br>In reproductive toxicology studies, evidence of impaired fertility was seen in female rats at doses providing systemic exposure, based on AUC, approximately equivalent to that provided with the recommended clinical dose of nevirapine.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="Section_13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<br><p class="First">Animal studies have shown that nevirapine is widely distributed to nearly all tissues and readily crosses the blood-brain barrier.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Adult Patients</h2>
<br><p class="First">Trial BI 1090 was a placebo-controlled, double-blind, randomized trial in 2249 HIV-1 infected subjects with less than 200 CD4<span class="Sup">+</span> cells/mm<span class="Sup">3</span> at screening. Initiated in 1995, BI 1090 compared treatment with nevirapine + lamivudine + background therapy versus lamivudine + background therapy in NNRTI-naïve subjects. Treatment doses were nevirapine, 200 mg daily for two weeks followed by 200 mg twice daily or placebo, and lamivudine, 150 mg twice daily. Other antiretroviral agents were given at approved doses. Initial background therapy (in addition to lamivudine) was one NRTI in 1309 subjects (58%), two or more NRTIs in 771 (34%), and PIs and NRTIs in 169 (8%). The subjects (median age 36.5 years, 70% Caucasian, 79% male) had advanced HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, with a median baseline CD4<span class="Sup">+ </span>cell count of 96 cells/mm<span class="Sup">3</span> and a baseline HIV-1 RNA of 4.58 log<span class="Sub">10</span> copies per mL (38,291 copies per mL). Prior to entering the trial, 45% had previously experienced an AIDS-defining clinical event. Eighty-nine percent had antiretroviral treatment prior to entering the trial. BI 1090 was originally designed as a clinical endpoint trial. Prior to unblinding the trial, the primary endpoint was changed to proportion of subjects with HIV-1 RNA less than 50 copies per mL and not previously failed at 48 weeks. Treatment response and outcomes are shown in Table 6. </p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 6 BI 1090 Outcomes Through 48 Weeks 
			</span></caption>
<thead><tr class="First Last">
<th class="Lrule Rrule Toprule">Outcome</th>
<th class="Lrule Rrule Toprule" align="center">Nevirapine<br>(N=1121)<br>%</th>
<th class="Lrule Rrule Toprule" align="center">Placebo<br>(N=1128)<br>%</th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="3">
<span class="Sup">1 </span>including change to open-label nevirapine <br><span class="Sup">2 </span>includes withdrawal of consent, lost to follow-up, non-compliance with protocol, other administrative reasons <br>
</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" valign="top"> Responders at 48 weeks: HIV-1 RNA &lt;50 copies/mL <br>
</td>
<td class="Rrule" align="center" valign="top">18<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> Treatment Failure <br>
</td>
<td class="Rrule" align="center" valign="top">82<br>
</td>
<td class="Rrule" align="center" valign="top">98<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    Never suppressed viral load<br>
</td>
<td class="Rrule" align="center" valign="top">45<br>
</td>
<td class="Rrule" align="center" valign="top">66<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    Virologic failure after response<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    CDC category C event or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> <br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
<td class="Rrule" align="center" valign="top">11<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    Added antiretroviral therapy<span class="Sup">1</span> while &lt;50 copies/mL <br>
</td>
<td class="Rrule" align="center" valign="top">5<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">    Discontinued trial therapy due to AE <br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">    Discontinued trial &lt;48 weeks<span class="Sup">2</span><br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
<td class="Rrule" align="center" valign="top">10<br>
</td>
</tr>
</tbody>
</table>
<p>The change from baseline in CD4<span class="Sup">+</span> cell count through one year of therapy was significantly greater for the nevirapine group compared to the placebo group for the overall trial population (64 cells/mm<span class="Sup">3 </span>versus 22 cells/mm<span class="Sup">3</span>, respectively), as well as for subjects who entered the trial as treatment-naïve or having received only ZDV (85 cells/mm<span class="Sup">3 </span>versus 25 cells/mm<span class="Sup">3</span>, respectively). <br><br>At two years into the trial, 16% of subjects on nevirapine had experienced class C CDC events as compared to 21% of subjects on the control arm. <br><br>Trial BI 1046 (INCAS) was a double-blind, placebo-controlled, randomized, three-arm trial with 151 HIV-1 infected subjects with CD4<span class="Sup">+</span> cell counts of 200 to 600 cells/mm<span class="Sup">3</span> at baseline. BI 1046 compared treatment with nevirapine+zidovudine+didanosine to nevirapine+zidovudine and zidovudine+didanosine. Treatment doses were nevirapine at 200 mg daily for two weeks followed by 200 mg twice daily or placebo, zidovudine at 200 mg three times daily, and didanosine at 125 or 200 mg twice daily (depending on body weight). The subjects had mean baseline HIV-1 RNA of 4.41 log<span class="Sub">10</span> copies/mL (25,704 copies per mL) and mean baseline CD4<span class="Sup">+</span> cell count of 376 cells/mm<span class="Sup">3</span>. The primary endpoint was the proportion of subjects with HIV-1 RNA less than 400 copies per mL and not previously failed at 48 weeks. The virologic responder rates at 48 weeks were 45% for subjects treated with nevirapine+zidovudine+didanosine, 19% for subjects treated with zidovudine+didanosine, and 0% for subjects treated with nevirapine+zidovudine.  <br><br>CD4<span class="Sup">+</span> cell counts in the nevirapine+ZDV+ddI group increased above baseline by a mean of 139 cells/mm<span class="Sup">3</span></p>
<span class="Sup"></span><p>at one year, significantly greater than the increase of 87 cells/mm<span class="Sup">3</span> in the ZDV+ddI subjects. The nevirapine+ZDV group mean decreased by 6 cells/mm<span class="Sup">3</span> below baseline.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Pediatric Patients</h2>
<br><p class="First">The pediatric safety and efficacy of nevirapine was examined in BI Trial 1100.1368, an open-label, randomized clinical trial performed in South Africa in which 123 HIV-1 infected treatment-naïve subjects between 3 months and 16 years of age received nevirapine oral suspension for 48 weeks. Subjects were divided into 4 age groups (3 months to less than 2 years, 2 to less than 7 years, 7 to less than 12 years, and 12 to less than or equal to 16 years) and randomized to receive one of two nevirapine doses, determined by 2 different dosing methods [body surface area (150 mg/m<span class="Sup">2</span>) and weight-based dosing (4 or 7 mg per kg)] in combination with zidovudine and lamivudine <span class="Italics">[see <a href="#Section_6.2">Adverse Reactions (6.2)</a>, <a href="#Section_8.4">Use in Specific Populations (8.4)</a>, and <a href="#Section_12.3">Clinical Pharmacology (12.3)</a>]</span>. The total daily dose of nevirapine did not exceed 400 mg in either regimen. There were 66 subjects in the body surface area (BSA) dosing group and 57 subjects in the weight-based (BW) dosing group.<br><br>Baseline demographics included: 49% male; 81% Black and 19% Caucasian; 4% had previous exposure to ARVs. Subjects had a median baseline HIV-1 RNA of 5.45 log<span class="Sub">10</span> copies per mL and a median baseline CD4<span class="Sup">+ </span>cell count of 527 cells/mm<span class="Sup">3</span> (range 37 to 2279). One hundred and five (85%) completed the 48-week period while 18 (15%) discontinued prematurely. Of the subjects who discontinued prematurely, 9 (7%) discontinued due to adverse reactions and 3 (2%) discontinued due to virologic failure. Overall the proportion of subjects who achieved and maintained an HIV-1 RNA less than 400 copies per mL at 48 weeks was 47% (58/123).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Bold">Nevirapine Oral Suspension, USP </span>is a white to off-white homogenous suspension containing 50 mg nevirapine (as nevirapine hemihydrate) in each 5 mL. Nevirapine suspension is supplied in HDPE bottles with child-resistant closures.<br><br>                         100 mL Bottle                           NDC 65862-057-11<br>                         240 mL Bottle                           NDC 65862-057-24<br><span class="Bold"><br><span class="Italics">Storage<br></span><br>Nevirapine Oral Suspension, USP should be stored at 20</span><span class="Bold">°</span><span class="Bold"> to 25</span><span class="Bold">°</span><span class="Bold">C (68</span><span class="Bold">°</span><span class="Bold"> to 77</span><span class="Bold">°</span><span class="Bold">F); excursions permitted to 15</span><span class="Bold">°</span><span class="Bold"> to 30</span><span class="Bold">°</span><span class="Bold">C (59</span><span class="Bold">°</span><span class="Bold"> to 86</span><span class="Bold">°</span><span class="Bold">F)</span> [see USP Controlled Room Temperature]. Store in a safe place out of the reach of children.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (Medication Guide).</p>
<br><ul class="Disc"><li><span class="Bold">Hepatotoxicity and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></span></li></ul>
<p><span class="Bold">Inform patients of the possibility of severe liver disease or <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> associated with nevirapine that may result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Instruct patients developing signs or symptoms of liver disease or severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> to discontinue nevirapine and seek medical attention immediately, including performance of laboratory monitoring. Symptoms of liver disease include <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, acholic stools, <span class="product-label-link" type="condition" conceptid="4010482" conceptname="Liver tender">liver tenderness</span> or <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>. Symptoms of severe skin or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> include <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> accompanied by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="43530620" conceptname="Oral lesion">oral lesions</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and/or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.</span></p>
<br><p>Intensive clinical and laboratory monitoring, including liver enzymes, is essential during the first 18 weeks of therapy with nevirapine to detect potentially life-threatening hepatotoxicity and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. However, liver disease can occur after this period; therefore, monitoring should continue at frequent intervals throughout nevirapine treatment. Extra vigilance is warranted during the first 6 weeks of therapy, which is the period of greatest risk of hepatic events and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. Advise patients with signs and symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> to discontinue nevirapine and seek medical evaluation immediately. If nevirapine is discontinued due to hepatotoxicity, do not restart it. Patients, particularly women, with increased CD4+ cell count at initiation of nevirapine therapy (greater than 250 cells/mm3 in women and greater than 400 cells/mm3 in men) are at substantially higher risk for development of symptomatic hepatic events, often associated with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Advise patients that co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C and/or increased transaminases at the start of therapy with nevirapine are associated with a greater risk of later symptomatic events (6 weeks or more after starting nevirapine) and asymptomatic increases in AST or ALT <span class="Italics">[see <a href="#Section_0">Boxed Warning</a> and <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
<br><p>The majority of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> associated with nevirapine occur within the first 6 weeks of initiation of therapy. Instruct patients that if any <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> occurs during the two-week lead-in period, do not escalate the nevirapine dose until the <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> resolves. The total duration of the once-daily lead-in dosing period should not exceed 28 days, at which point an alternative regimen may need to be started. Any patient experiencing a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> should have their liver enzymes (AST, ALT) evaluated immediately. Patients with severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> should discontinue nevirapine immediately and consult a physician. Nevirapine should not be restarted following severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span>. Women tend to be at higher risk for development of nevirapine-associated <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> <span class="Italics">[see <a href="#Section_0">Boxed Warning</a> and <a href="#Section_5.2">Warnings and Precautions (5.2)</a>]</span>.</p>
<br><ul class="Disc"><li><span class="Bold">Administration</span></li></ul>
<p>Inform patients to take nevirapine every day as prescribed. Patients should not alter the dose without consulting their doctor. If a dose is missed, patients should take the next dose as soon as possible. However, if a dose is skipped, the patient should not double the next dose. Advise patients to report to their doctor the use of any other medications.</p>
<br><p>Nevirapine is not a cure for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>; patients may continue to experience illnesses associated with advanced HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. Advise patients to remain under the care of a physician when using nevirapine.</p>
<br><p>Patients should be told that sustained decreases in plasma HIV RNA have been associated with a reduced risk of progression to AIDS and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<br><p>Advise patients to avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others.</p>
<br><ul class="Disc">
<li><span class="Bold">Do not share needles or other injection equipment.</span></li>
<li><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</span></li>
<li>
<span class="Bold">Do not have any kind of sex without protection.</span> Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</li>
<li>
<span class="Bold">Do not </span><span class="Bold">breastfeed</span>. We do not know if nevirapine can be passed to your baby in your breast milk and whether it could harm your baby. Also, mothers with HIV-1 should not breastfeed because HIV-1 can be passed to the baby in the breast milk.</li>
</ul>
<br><p>Inform patients that they should not take nevirapine tablets or oral suspension and nevirapine extended release tablets at the same time.</p>
<br><ul class="Disc"><li><span class="Bold">Drug Interactions</span></li></ul>
<p>Nevirapine may interact with some drugs; therefore, patients should be advised to report to their doctor the use of any other prescription, non-prescription medication or herbal products, particularly St. John's wort <span class="Italics">[see <a href="#Section_5.4">Warnings and Precautions (5.4)</a> and <a href="#Section_7">Drug Interactions (7)</a>]</span>.</p>
<br><ul class="Disc"><li><span class="Bold">Contraceptives</span></li></ul>
<p>Hormonal methods of birth control, other than depomedroxy-progesterone acetate (DMPA), should not be used as the sole method of contraception in women taking nevirapine, since nevirapine may lower the plasma levels of these medications. Additionally, when oral contraceptives are used for hormonal regulation during nevirapine therapy, the therapeutic effect of the hormonal therapy should be monitored <span class="Italics">[see <a href="#Section_7">Drug Interactions (7)</a>]</span>.</p>
<br><ul class="Disc"><li><span class="Bold">Methadone</span></li></ul>
<p>Nevirapine may decrease plasma concentrations of methadone by increasing its hepatic metabolism. Narcotic withdrawal syndrome has been reported in patients treated with nevirapine and methadone concomitantly. Monitor methadone-maintained patients beginning nevirapine therapy for evidence of withdrawal and adjust methadone dose accordingly <span class="Italics">[see <a href="#Section_7">Drug Interactions (7)</a>]</span>.</p>
<br><ul class="Disc"><li><span class="Bold">Fat Redistribution</span></li></ul>
<p>Inform patients that redistribution or accumulation of body fat may occur in patients receiving antiretroviral therapy and that the cause and long-term health effects of these conditions are not known at this time <span class="Italics">[see <a href="#Section_5.6">Warnings and Precautions (5.6)</a>]</span>.<br><br>Manufactured for:<br><span class="Bold">Aurobindo Pharma USA, Inc.<br></span>2400 Route 130 North<br>Dayton, NJ 08810<br><br>Manufactured by:<br><span class="Bold">Aurobindo Pharma Limited<br></span>Hyderabad-500 090, India<br><br>Revised: 04/2015</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="Section_19"></a><a name="section-16"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">Nevirapine Oral Suspension, USP</span></p>
<p><span class="Bold">(ne vir' a peen)</span></p>
<br><p><span class="Bold">Read this Medication Guide before you start taking nevirapine oral suspension and each time you get a refill.</span> There may be new information. This information does not take the place of talking to your doctor about your medical condition or treatment.</p>
<br><p><span class="Bold">What is the most important information I should know about nevirapine oral suspension?</span></p>
<p><span class="Bold">Nevirapine oral suspension can cause serious side effects. These include severe liver and skin problems that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. These problems can happen at any time during treatment, but your risk is higher during the first 18 weeks of treatment.</span></p>
<br><p><span class="Bold">1.   Severe liver problems: </span>Anyone who takes nevirapine oral suspension may get severe liver problems. In some cases these liver problems can lead to <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> and the need for a liver transplant, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<br><p>People who have a higher CD4<span class="Sup">+</span> cell count when they begin nevirapine oral suspension treatment have a higher risk of liver problems, especially:</p>
<br><ul class="Disc">
<li>Women with CD4<span class="Sup">+</span>counts higher than 250 cells/mm<span class="Sup">3</span>. This group has the highest risk.</li>
<li>Men with CD4<span class="Sup">+</span> counts higher than 400 cells/mm<span class="Sup">3</span>.</li>
</ul>
<br><p>If you are a woman with CD4<span class="Sup">+</span>counts higher than 250 cells/mm<span class="Sup">3</span> or a man with CD4<span class="Sup">+</span> counts higher than 400 cells/mm<span class="Sup">3</span>, you and your doctor will decide whether starting nevirapine oral suspension is right for you. </p>
<br><p>In general, women have a higher risk of liver problems compared to men. </p>
<br><p>People who have abnormal liver test results before starting nevirapine oral suspension treatment and people with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C also have a greater risk of getting liver problems.  </p>
<br><p>You may get a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> if you have liver problems.</p>
<br><p><span class="Bold">Stop taking nevirapine oral suspension and call your doctor right away if you have any of the following symptoms of liver problems: </span></p>
<br><ul class="Disc">
<li>dark (tea colored) urine</li>
<li>yellowing of your skin or whites of your eyes</li>
<li>light-colored bowel movements (stools)</li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (feeling sick to your stomach)</li>
<li>feel unwell or like you have the flu</li>
<li><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> on your right side below your ribs</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li>loss of appetite</li>
</ul>
<br><p>Your doctor should see you and do blood tests often to check your liver function during the first 18 weeks of treatment with nevirapine oral suspension. You should continue to have your liver checked regularly during your treatment with nevirapine oral suspension. It is important for you to keep all of your doctor appointments. </p>
<br><p><span class="Bold">2.   Severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>: </span><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> is the most common side effect of nevirapine oral suspension. Most <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> happen in the first 6 weeks of taking nevirapine oral suspension. <span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rashes</span> and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may be severe, life-threatening, and in some people, may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Stop using nevirapine oral suspension and call your doctor right away if you get a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with any of the following symptoms:</span></p>
<br><p>•     <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span><br>•     mouth sores<br>•     red or inflamed eyes, like “pink eye? (<span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>)<br>•     liver problems (see symptoms of liver problems above)<br>•     <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face<br>•     <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span><br>•     feel unwell or like you have the flu<br>•     <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span><br>•     muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span></p>
<br><p><span class="Bold">If your doctor tells you to stop treatment with nevirapine oral suspension because you have had any of the serious liver or skin problems described above, you should never take nevirapine oral suspension again. </span></p>
<br><p>See the section <span class="Bold">“What are the possible side effects of nevirapine oral suspension?? </span>for more information.</p>
<br><p><span class="Bold">What is nevirapine oral suspension? </span></p>
<br><p>•     Nevirapine oral suspension is prescription HIV medicines used with other HIV medicines to treat HIV (Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus). HIV is the virus that causes AIDS (<span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">Acquired Immune Deficiency Syndrome</span>). </p>
<br><p>•     Nevirapine is a type of HIV medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI).</p>
<br><p>When used with other HIV medicines, nevirapine oral suspension may:</p>
<br><p>1.  Reduce the amount of HIV in your blood (called “viral load?).</p>
<p>2.  Help increase the number of CD4 (T) cells in your blood which help fight off other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<br><p>Reducing the amount of HIV and increasing the CD4 (T) cell count may improve your immune system. This may reduce your risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that can happen when your immune system is weak (<span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>).</p>
<br><p><span class="Bold">Nevirapine oral suspension do not cure <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> or AIDS. </span></p>
<p>Nevirapine oral suspension do not cure HIV or AIDS and you may continue to experience illnesses associated with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. You should remain under the care of a doctor when using nevirapine oral suspension. </p>
<br><p>You must stay on continuous HIV therapy to control <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> and decrease HIV-related illnesses.</p>
<br><p>Avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others:</p>
<p>•     <span class="Bold">Do not share needles or other injection equipment.<br></span><span class="Bold">•     Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.<br></span><span class="Bold">•     Do not have any kind of sex without protection.</span> Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</p>
<br><p>Ask your doctor if you have any questions on how to prevent passing HIV to other people. </p>
<br><p><span class="Bold">Who should not take nevirapine oral suspension? </span></p>
<br><p>Tell your doctor if you have or have had liver problems. Your doctor may tell you not to take nevirapine oral suspension if you have certain liver problems. </p>
<br><p>Nevirapine oral suspension is only for people diagnosed with HIV. If you have not been diagnosed as HIV positive, then do not take nevirapine oral suspension.</p>
<br><p><span class="Bold">What should I tell my doctor before taking nevirapine oral suspension?</span></p>
<p><span class="Bold">Before you take nevirapine oral suspension, tell your doctor if you:</span></p>
<p>•     have or have had <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of your liver) or problems with your liver. See <span class="Bold">“What is the most important information I should know about nevirapine oral suspension?? </span>and<span class="Bold"> “Who should not take nevirapine oral suspension??<br></span>•     receive dialysis<br>•     have skin problems, such as a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span><br>•     or your child has trouble swallowing pills<br>•     have any other medical conditions<br>•     are pregnant or plan to become pregnant. It is not known if nevirapine oral suspension will harm your unborn baby.<br><span class="Bold">Pregnancy Registry:</span> There is a pregnancy registry for women who take antiviral medicines during pregnancy. The purpose of the registry is to collect information about the health of you and your baby. Talk to your doctor about how you can take part in this registry.<br>•     are breast-feeding or plan to breast-feed. Nevirapine can pass into your breast milk and may harm your baby. You should not breastfeed if you have HIV because of the risk of passing HIV to your baby. Do not breast-feed during treatment with nevirapine oral suspension. Talk to your doctor about the best way to feed your baby</p>
<br><p><span class="Bold">Tell your doctor and pharmacist about all the medicines you take,</span> including prescription and over-the-counter medicines, vitamins and herbal supplements. Nevirapine oral suspension may affect the way other medicines work, and other medicines may affect how nevirapine oral suspension works. </p>
<br><p>You should not take nevirapine oral suspension if you also take:</p>
<p>•     St. John’s Wort. St. John’s Wort can lower the amount of nevirapine in your body.<br>•     efavirenz (Sustiva<span class="Sup">®</span>, Atripla<span class="Sup">®</span>), etravirine (Intelence<span class="Sup">®</span>), rilpivirine (Edurant<span class="Sup">®</span> Complera<span class="Sup">®</span>), or  delavirdine (Rescriptor<span class="Sup">®</span>)<br>•     boceprevir (Victrelis<span class="Sup">®</span>)<br>•     telaprevir (Incivek<span class="Sup">®</span>)<br>•     atazanavir (Reyataz<span class="Sup">®</span>)<br>•     lopinavir and ritonavir (Kaletra<span class="Sup">®</span>) once daily<br>•     fosamprenavir calcium (Lexiva<span class="Sup">®</span>) without ritonavir (Norvir<span class="Sup">®</span>)<br>•     itraconazole (Sporanox<span class="Sup">®</span>)<br>•     ketoconazole (Nizoral<span class="Sup">®</span>)<br>•     rifampin (Rifadin<span class="Sup">®</span>, Rifamate<span class="Sup">®</span>, Rifater<span class="Sup">®</span>)<br>•     birth control pills. Birth control pills taken by mouth (oral contraceptives) and other hormone types of birth control may not work to prevent pregnancy. Talk with your doctor about other types of birth control that you can use to prevent pregnancy during treatment with nevirapine oral suspension.</p>
<br><p>Also tell your doctor if you take:<br>•     clarithromycin (Biaxin<span class="Sup">®</span>)<br>•     fluconazole (Diflucan<span class="Sup">®</span>)<br>•     indinavir sulfate (Crixivan<span class="Sup">®</span>)<br>•     methadone<br>•     nelfinavir mesylate (Viracept<span class="Sup">®</span>)<br>•     rifabutin (Mycobutin<span class="Sup">®</span>)<br>•     warfarin (Coumadin<span class="Sup">®</span>, Jantoven<span class="Sup">®</span>)<br>•     saquinavir mesylate (Invirase<span class="Sup">®</span>)<br>•     amiodarone, disopyramide (Norpace<span class="Sup">®</span>), lidocaine<br>•     carbamazepine, clonazepam (Klonopin<span class="Sup">®</span>), ethosuximide (Zarontin<span class="Sup">®</span>)<br>•     diltiazem, nifedipine, verapamil<br>•     cyclophosphamide<br>•     ergotamine<br>•     cyclosporine, tacrolimus, sirolimus (Rapamune<span class="Sup">®</span>)<br>•     cisapride (Propulsid<span class="Sup">®</span>)<br>•     fentanyl</p>
<br><p><span class="Bold">If you are not sure if you take a medicine above, ask your doctor or pharmacist.</span></p>
<br><p>Know the medicines you take. Keep a list of them to show your doctor or pharmacist when you get a new medicine.</p>
<br><p><span class="Bold">How should I take nevirapine oral suspension?  </span></p>
<br><p>•     Nevirapine oral suspension is always taken in combination with other anti-HIV medications.<br>•     Take nevirapine oral suspension exactly as your doctor tells you to take it. Do not change your dose unless your doctor tells you to.<br>•     You should never take more than one form of nevirapine at the same time. Talk to your doctor if you have any questions.<br>•     If your child is prescribed nevirapine oral suspension, your child’s doctor will tell you exactly how nevirapine oral suspension should be taken.<br>•     You may take nevirapine oral suspension with or without food.<br>•     Do not miss a dose of nevirapine oral suspension. If you miss a dose of nevirapine oral suspension, take the missed dose as soon as you remember. If it is almost time for your next dose, do not take the missed dose, just take the next dose at your regular time. Do not take two doses at the same time.<br>•     If you stop taking nevirapine oral suspension for more than 7 days, ask your doctor how much to take before you start taking it again. You may need to begin taking the nevirapine oral suspension starting dose again, which is taken 1 time each day for 14 days.<br>•     Your doctor should start you with 1 dose each day to lower your chance of getting a serious <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. <span class="Bold">It is important that you only take 1 dose of nevirapine oral suspension each day for the first 14 days</span>.<br>•     <span class="Bold">Call your doctor right away if you get a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> during the first 14 days of nevirapine oral suspension treatment.</span><br>•     <span class="Bold">Do not increase your dose to 2 times a day if you have a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</span><br>•     You should never take your starting dose for longer than 28 days. If after 28 days you are still receiving this starting dose because you have a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, you and your doctor should talk about prescribing another HIV medicine for you instead of nevirapine oral suspension.</p>
<br><p><span class="Bold">Switching from nevirapine oral suspension to nevirapine extended-release tablets: </span></p>
<br><p>Take nevirapine extended-release tablets 1 time a day as prescribed by your doctor.</p>
<br><p>You may sometimes pass a soft <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> in your stools (bowel movement) that looks like your nevirapine extended-release tablets. This will not affect the way your medicine works.</p>
<br><p><span class="Bold">If you take nevirapine oral suspension:</span></p>
<p>•     If you or your child takes nevirapine oral suspension (liquid), shake it gently before each use. Use an oral dosing syringe or dosing cup to measure the right dose. The oral dosing syringe and dosing cup are not provided with nevirapine oral suspension. Ask your pharmacist for a syringe or cup if you do not have one.<br>•     After drinking the medicine, fill the dosing cup with water and drink it to make sure you get all the medicine.<br>•     If the dose is less than 1 teaspoon (5 mL), use the syringe instead of the dosing cup.</p>
<br><p><span class="Bold">What are the possible side effects of nevirapine oral suspension? </span></p>
<br><p>Nevirapine oral suspension may cause serious side effects, including:</p>
<br><p>See <span class="Bold">“What is the most important information I should know about nevirapine oral suspension??</span></p>
<br><p>•     <span class="Bold">Changes in your immune system (<span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span>)</span> can happen when you start taking HIV medicines. Your immune system may get stronger and begin to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that have been hidden in your body for a long time. Tell your doctor if you start having new symptoms after starting your HIV medicine.</p>
<p>•     <span class="Bold">Changes in body fat</span> can happen in some people who take antiretroviral therapy. These changes may include increased amount of fat in the upper back and neck (“buffalo hump?), breast, and around the middle of your body (trunk). Loss of fat from your legs, arms, and face can also happen. The cause and long-term health effects of these problems are not known at this time.</p>
<br><p><span class="Bold">The most common side effect of nevirapine oral suspension is <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</span></p>
<br><p>Tell your doctor if you have any side effect that bothers you or that does not go away. </p>
<br><p>These are not all the possible side effects of nevirapine oral suspension. For more information, ask your doctor or pharmacist.</p>
<br><p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<br><p><span class="Bold">How should I store nevirapine oral suspension? </span></p>
<br><p>•     Nevirapine oral suspension should be stored at 20° to 25°C (68° to 77°F) excursions permitted to 15° to 30°C (59° to 86°F). Throw away nevirapine oral suspension that is no longer needed or out-of-date.</p>
<br><p><span class="Bold">Keep nevirapine oral suspension and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about nevirapine oral suspension.</span></p>
<br><p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not take nevirapine oral suspension for a condition for which it was not prescribed. Do not give nevirapine oral suspension to other people, even if they have the same condition you have. It may harm them.</p>
<br><p>This Medication Guide summarizes the most important information about nevirapine oral suspension. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about nevirapine oral suspension that is written for health professionals.</p>
<br><p>For more information, call Aurobindo Pharma USA, Inc. at 1-866-850-2876. </p>
<br><p><span class="Bold">What are the ingredients in nevirapine oral suspension?</span></p>
<br><p>Active ingredient: nevirapine </p>
<br><p>Inactive ingredients: carbopol 974PNF, methylparaben, propylparaben, non crystallizing sorbitol solution, sucrose, propylene glycol, polysorbate 80, sodium hydroxide, and purified water.<br><br>Manufactured for:<br><span class="Bold">Aurobindo Pharma USA, Inc.<br></span>2400 Route 130 North<br>Dayton, NJ 08810<br><br>Manufactured by:<br><span class="Bold">Aurobindo Pharma Limited<br></span>Hyderabad-500 090, India<br><br>Revised: 04/2015<br><span class="Bold"><br>This Medication Guide has been approved by the U.S. Food and Drug Administration.<br></span><br>The brands listed are trademarks of their respective owners and are not trademarks of Aurobindo Pharma Limited.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_20"></a><a name="section-17"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 50 mg/5 mL (240 mL Bottle)</h1>
<br><p class="First"><span class="Bold">NDC 65862-057-24</span><br><span class="Bold">Nevirapine Oral </span><span class="Bold">Suspension, USP</span><br><span class="Bold">50 mg/5 mL*</span><br><span class="Bold">PHARMACIST: Dispense the accompying</span><br><span class="Bold">Medication Guide to each patient.</span><br><span class="Bold">Rx only         240 mL</span><br><span class="Bold">AUROBINDO<br><br><img alt="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 50 mg/5 mL (240 mL Bottle)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8dfe86aa-ea5d-48d2-94a8-1a5506055d70&amp;name=nevirapine-fig2.jpg"><br><br></span> </p>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NEVIRAPINE 		
					</strong><br><span class="contentTableReg">nevirapine suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:65862-057</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NEVIRAPINE HEMIHYDRATE</strong> (NEVIRAPINE) </td>
<td class="formItem">NEVIRAPINE</td>
<td class="formItem">50 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOMER HOMOPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (White to Off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:65862-057-11</td>
<td class="formItem">100 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:65862-057-24</td>
<td class="formItem">240 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077702</td>
<td class="formItem">05/22/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Aurobindo Pharma Limited
							(650082092)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Aurobindo Pharma Limited</td>
<td class="formItem"></td>
<td class="formItem">918917642</td>
<td class="formItem">ANALYSIS(65862-057), MANUFACTURE(65862-057)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Aurobindo Pharma Limited</td>
<td class="formItem"></td>
<td class="formItem">918917647</td>
<td class="formItem">API MANUFACTURE(65862-057)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>078f8618-ef98-406a-97b6-a8144be3184a</div>
<div>Set id: 8dfe86aa-ea5d-48d2-94a8-1a5506055d70</div>
<div>Version: 4</div>
<div>Effective Time: 20150428</div>
</div>
</div> <div class="DistributorName">Aurobindo Pharma Limited</div></p>
</body></html>
